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Qualitative Metabolic Profiling of S3643 Using Human and Rat Mixed 
Gender Pooled Hepatic Microsomes 
PharmOptima Study No. 2011-156 
Senomyx Study No. S3643-PK2 
 
Incubation of S3643 with rat and human liver microsomes 
A stock solution of S3643 was prepared at 2.0 mM in methanol.  Exactly 13.9 µL of 2.0 mM 
S3643 was added to 2.5 mL of human and rat microsomes (0.556 mg/mL in potassium phosphate 
buffer).  Two hundred and twenty-five µL of microsomes containing S3643 were aliquoted to 
1.5 mL microcentrifuge tubes.  At this point, 0 minute incubation samples received 500 µL of 
acetonitrile.  Samples then received 25 µL of either potassium phosphate buffer (minus NADPH 
control) or potassium phosphate buffer containing 14.4 mM NADPH.  Samples were then 
incubated at 37°C for 60 minutes.  (The final microsome concentration for each species was 
0.50 mg/mL; the final concentration of S3643 was 10 µM).  After 60 minutes, 500 µL of 
acetonitrile was added to samples to quench all microsomal activity.  Samples were then 
centrifuged at 14,000 rpm for 10 minutes at 4°C to separate the precipitated microsomes from the 
supernatant containing S3643 and its potential metabolites.  The samples were stored at -80°C 
until analysis, when they were thawed at room temperature, and analyzed in a chilled 
autosampler at 10°C.   
 
Control Microsome Incubations for Testosterone 
A stock solution of testosterone was prepared at 20 mM in methanol.  Exactly 8.3 µL of 
testosterone 20 mM stock was added to 1.50 mL of pooled mixed gender human and rat 
microsomes at 0.556 mg/mL.  Two hundred and twenty-five µL of microsomes containing 
testosterone were aliquoted to 1.5 mL microcentrifuge tubes.  At this point, samples received 25 
µL of either potassium phosphate buffer (minus NADPH control) or 14.4 mM NADPH in 
potassium phosphate buffer.  Samples were incubated at 37°C for 60 minutes.  (The final 
microsome concentration for each species was 0.50 mg/mL; the final concentration of 
testosterone was 99.1 µM).  After 60 minutes, 500 µL of acetonitrile was added to samples to 
quench all microsomal activity.  Samples were centrifuged at 14,000 rpm for 10 minutes at 4°C 
to separate the precipitated microsomes from the supernatant containing testosterone and 
metabolites.  The samples were stored at -80°C until analysis, when they were thawed at room 





HPLC pump:   Thermo Electron Accela Pump 
Autosampler:   LEAP Technologies HTC PAL 
Injection volume:  10 µL 
Flow rate:   0.300 mL/min 
Mobile Phase:   A: 1 mM ammonium acetate in water 
    B: 1 mM ammonium acetate in methanol 
Gradient:   0.0 – 1.0 min isocratic 5% B 
1.0 – 5.5 min linear gradient 5 – 100% B 
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5.5 – 6.5 min isocratic at 100% B 
6.6 – 10.0 min re-equilibrate at 5% B 
Column: Phenomenex Kinetex C18, 2.6 µm, 50 × 2.1 mm, 100 Å pore size, 
with guard column. 
 
ESI + MS Conditions 
Instrument:   Thermo Electron Quantum Access 
Ionization:   Heated Electrospray (HESI) 
Resolution:   0.7 Thompsons (Th) at half peak height 
Spray Voltage:  5000 V 
Vaporizer Temperature: 325°C 
Sheath Gas Pressure:  30 psi 
Auxiliary Gas Pressure: 25 (arbitrary Thermo units) 
Sweep Gas pressure:  5 (arbitrary Thermo units) 
Capillary Temperature: 350°C 
Tube Lens Offset:  77 
Skimmer Offset:  6 
 
ESI - MS Conditions 
Instrument:   Thermo Electron Quantum Access 
Ionization:   Heated Electrospray (HESI) 
Resolution:   0.7 Thompsons (Th) at half peak height 
Spray Voltage:  2500 V 
Vaporizer Temperature: 200°C 
Sheath Gas Pressure:  30 psi 
Auxiliary Gas Pressure: 25 (arbitrary Thermo units) 
Sweep Gas pressure:  5 (arbitrary Thermo units) 
Capillary Temperature: 250°C 
Tube Lens Offset:  -77 
Skimmer Offset:  2 
 
LC-QTOF/MS Analysis 
Samples from duplicate incubations with rat microsomes were also analyzed using an LC-
QTOF/MS (Agilent iFunnel 6550A MS Q-TOF) equipped with an Agilent 1290 Infinity Binary 
pump and an Agilent 1290 Infinity autosampler.  The HPLC and MS conditions are described in 






HPLC pump Agilent 1290 Infinity Binary pump 
Autosampler Agilent 1290 Infinity Autosampler 
Column Zorbax Eclipse Plus C18, 2.1 x 50 mm, 1.8 m 
Mobile Phase A 2 mM Ammonium acetate and 0.1 % formic acid in water 
Mobile Phase B Methanol 
Flow Rate 1.0 mL/min 
Injection Volume 1.0 L 
Column Temperature 40 C 
Gradient 
Time (min)     %B  Valve switch 
0.0        5  1 => 2 
0.2        5 
6.5                        40 
7.5                        95 
8.5                        95 
8.51                       5 
10.0                       5 
Acquisition Time 10.0 min 
S3643 Retention Time ~ 5.79 min 
 
Mass Spectrometric Conditions 
Instrument Agilent iFunnel 6550A MS Q-TOF  
Ionization Source Dual AJS ESI 
Polarity Positive 
Gas Temp (◦C) 275 
Gas Flow (L/min) 13 
Nebulizer (psig) 30 
SheathGasTemp (◦C) 375 
SheathGasFlow (L/min) 12 
VCap (V) 3250 
Nozzle Voltage (V) 0 
Fragmentor (V) 125 
Ref Mass Enabled Enabled 
Ref Nebulizer (psig) 5 






Figure 1. +ESI Extracted Ion Chromatogram of Four Synthetic Standards and m/z 
345.1016 Metabolites M344A (RT = 5.35 min) and M344 B (RT = 4.27 min) in Rat Liver 






The structure of metabolite M344A was confirmed to be the corresponding S3643-sulfoxide (i.e., 
S2519).  The structure of metabolite M344B was confirmed to be the 4’-hydroxy derivative of 
S3643 (i.e., S9433).  The corresponding 5’- and 6’-hydroxy analogs (S5741 and S5744, 







Table 1. Major Metabolites of S3643 in Rat and Human Microsomal Incubations 
 












 345.1015 (M+H), 327.0901, 268.1082, 238.0641, 




 345.1016 (M+H), 312.0672, 222.0873, 207.0641, 









 315.0908 (M+H), 300.0667, 282.1107, 192.0765, 




 331.0859 (M+H), 313.0766, 192.0773, 93.0570 4.97 
M330B 331.0859 C15H15N4O3S
+
 331.057 (M+H), 299.0591, 192.0765, 93.0570 4.05 
M330C 331.0859 C15H15N4O3S
+
 331.0849 (M+H), 254.0674, 208.0714, 193.0480, 









 301.0749 (M+H), 268.0958, 239.0820, 178.0609, 
150.0653, 124.0213, 93.0573 
4.00 
 
    a. Retention time using a Zorbax Eclipse Plus C18 column (50 x 2.1 mm, 1.8 μm) and 2 mM ammonium    
        acetate/0.1% formic acid/water and methanol gradient system described above  
 
































Figure 2g.  Proposed Fragmentation of M330B 
 
 













Pharmacokinetics and Bioavailability of S3643 in Sprague-Dawley Rats 
Senomyx Study No. S3643-PK1 
 
Experimental Study Design 
The sixteen male and sixteen female Sprague-Dawley rats were assigned to the study as 















1 S3643 4 PO 
1% methyl 
cellulose
 10 Male 
































S3643 was administered once for group 1 to 6 via oral gavage and for group 7 to 8 via 
intravenous bolus injection.  The dose levels for the treated group 1 to 6 were 10, 30, and 100 
mg/kg at a dose volume of ~10 mL/kg.  The dose level for the treated group 7 and 8 was 1 mg/kg 
at a dose volume of ~5 mL/kg.  Each dose was based on the most recent body weight. 
 
Sample Collection, Handling, Storage, and Transfer 
Blood samples were collected from a jugular catheter into tubes containing K2EDTA as the 
anticoagulant.  Samples were collected from group 1 to 6 at approximately 0, 15, 30 min, 1, 2, 4, 
8, and 24 hours post dose.  Samples were collected from group 7 and 8 at approximately 0, 2, 5, 
10, 30 min, 1, 2, 4, and 8 hours post-dose.  The samples were stored on ice for no more than one 
hour until centrifuged at 2 to 7 C. The plasma samples were placed on dry ice prior to storage at 
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approximately -70 C.  Samples were protected from direct sunlight during collection and 
processing.  Samples were transferred to the Analytical Department at the test facility for 
analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). 
 
Plasma Sample Preparation 
On the day of analysis, the plasma samples were thawed at room temperature .  Proteins from 
plasma samples (25 µL) were precipitated by addition of 75 µL of acetonitrile containing 25 
ng/mL of the internal standard (S9767).  After 10 minutes of centrifugation (Sorvall Legend 
XTR, 6,000 rpm, 10 C), 50 µL of the resulting supernatant was mixed with 100 µL deionized 
water.  The solution was analyzed by LC-MS/MS. 
 
LC-MS/MS Analysis 
The prepared plasma samples were analyzed using an LC-MS/MS (Applied Biosystems) 
equipped with an Agilent 1100 binary pump and a CTC PAL injector.  S3643 and S9767 
(internal standard = IS) were detected using the ion transitions (329.1/206.1 for S3643 and 
297.1/174.1 for IS).  The calibration curve, obtained by spiking known concentrations of S3643 
to blank rat plasma, ranged from 2 ng/mL to 1000 ng/mL for both IV and oral dose.  The lower 
limit of quantitation (LLOQ) for S3643 was 2 ng/mL.  The HPLC and MS conditions are 





 C18, 2.1 mm x 50 mm, 3.5 um, Waters 
Mobile Phase A 0.1% formic acid in water 
Mobile Phase B 0.1% formic acid in acetonitrile 
Flow Rate 0.7 mL/min 
Injection Volume 10 L 
Column Temperature Room temperature 
Gradient Time (min) %B  Valve switch 
0.0    5  Not used 
1.5    95   
2.0                     95 
2.01                   5 
3.5                     5 
Acquisition Time  3.5 min 
S3643 Retention Time  ~ 1.78 min 






Mass Spectrometric Conditions 
Instrument API 3200 Q Trap 
Ionization Mode TurboIonspray 
Polarity Positive 
 
Scan Function Multiple Reaction Monitoring 
(MRM) 
Parameters S3643 S9767 (IS) 
 Precursor Ion 329.1 297.1 
Product Ion 206.1 174.1 
Dwell Time (ms) 100 100 
DP - Declustering Potential  (V) 55 55 
CE - Collision Energy (eV) 28 28 
CXP – Collision Cell Exit Potential (V) 4 4 
EP-Entrance Potential (V) 10 10 








TEM – Turbo Gas Temperature (C) 
GS1 – Ion Source Gas 1 
GS2 – Ion Source Gas 2 
CUR – Curtain Gas 
CAD – Collision Gas 
Resolution 










Table 2.  Concentrations and Pharmacokinetic Parameters of S3643 in Plasma Following 
Single Intravenous Administration to Sprague-Dawley Rats 
 
 Time (hr)      













male 1 Rat_13 LLOQ 12240 6770.2 3758.4 724.3 141.3 112.6 63.7 72.2 2955.9 12240.0 0.03 0.16 
 Rat_14 LLOQ 11141 5318.2 3102.2 677.3 211.2 96.0 71.4 32.7 2629.0 11141.0 0.03 0.18 
 Rat_15 LLOQ 11936 6208.4 3399.0 697.4 366.1 101.7 77.7 36.4 2946.6 11936.0 0.03 0.20 
 Rat_16 LLOQ 8154.1 7534.2 2876.6 606.4 373.8 77.9 92.2 58.0 2627.0 8154.1 0.03 0.21 
 N 0 4 4 4 4 4 4 4 4 4 4 4 4 
 Mean  10867.8 6457.8 3284.1 676.3 273.1 97.1 76.2 49.8 2789.6 10867.8 0.03 0.19 
 SD  1867.5 934.0 381.8 50.4 115.5 14.5 12.1 18.7 186.7 1867.5 0.00 0.02 
female 1 Rat_29 LLOQ 7938.2 4749.9 2770.2 581.2 113.3 38.7 35.2 17.5 1934.6 7938.2 0.03 0.16 
 Rat_30 LLOQ 8522.1 4204.5 2283.4 383.6 100.7 77.1 40.5 33.9 1875.9 8522.1 0.03 0.16 
 Rat_31 LLOQ 11484 5032.9 2495.3 299.7 88.1 43.8 17.1 12.8 1994.1 11484.0 0.03 0.14 
 Rat_32 LLOQ 11430 5152.4 3164.2 636.9 147.5 94.6 83.1 34.7 2634.8 11430.0 0.03 0.16 
 N 0 4 4 4 4 4 4 4 4 4 4 4 4 
 Mean  9843.6 4784.9 2678.3 475.3 112.4 63.6 43.9 24.7 2109.8 9843.6 0.03 0.16 
 SD  1878.3 422.2 380.3 159.8 25.6 26.8 27.9 11.2 353.3 1878.3 0.00 0.01 







Table 3.  Concentrations and Pharmacokinetic Parameters of S3643 in Plasma Following 




    
0.00 0.25 0.50 1.00 2.00 4.00 8.00 24.00 














male 10 Rat_1 LLOQ 26621 18652 6480.4 275.2 76.8 15.1 3.6 19333 26621 0.25 0.78 
 
Rat_2 LLOQ 41239 26242 13662 1631 151.6 35.3 LLOQ 33369 41239 0.25 0.79 
 
Rat_3 LLOQ 29661 19320 11025 1565.7 639.3 26.5 LLOQ 27248 29661 0.25 0.82 
 








7713.4 4202.5 3632.8 764.6 305.4 10.1 
 
7037 7713.4 0.00 0.02 
male 30 Rat_5 LLOQ 48512 62005 49740 7819.5 1055.8 324.5 11.2 90916 62005 0.50 0.97 
 
Rat_6 LLOQ 36166 34816 17817 4064.6 587.7 101.3 LLOQ 43523 36166 0.25 0.90 
 
Rat_7 LLOQ 51638 53219 48248 19585 4744.1 170.8 4.8 114409 53219 0.50 0.89 
 
Rat_8 LLOQ 43164 52130 30719 7529.8 2296.5 455.7 LLOQ 72475 52130 0.50 1.13 
 








6775.9 11378 15229 6775.1 1860.8 158.7 4.5 29944 10760 0.13 0.11 
male 100 Rat_9 LLOQ 64104 49438 28525 17133 7796.1 1837.4 9.8 123499 64104 0.25 1.67 
 
Rat_10 LLOQ 58982 84190 69190 31746 18176 2268.7 14.7 223161 84190 0.50 1.46 
 
Rat_11 LLOQ 83440 69046 51380 24270 4972.1 6537 43.5 202327 83440 0.25 2.12 
 
Rat_12 LLOQ 81360 79993 59164 26163 10553 1808.4 71.3 184268 81360 0.25 1.39 
 








12252 15526 17304 6032.3 5678.3 2292.4 28.5 42926 9521.9 0.13 0.33 
female 10 Rat_17 LLOQ 4248.6 2096.4 895.5 574.9 244.4 16.3 LLOQ 4148 4248.6 0.25 1.20 
 
Rat_18 LLOQ 22112 12491 3361.1 448.7 95.3 6.6 LLOQ 13705 22112 0.25 0.74 
 
Rat_19 LLOQ 19296 17101 10874 2817.7 702.2 14.3 LLOQ 25754 19296 0.25 0.74 
 
Rat_20 LLOQ 13896 8321.4 4618.4 1321 408.3 20.7 LLOQ 13306 13896 0.25 0.89 
 




14888 10003 4937.3 1290.6 362.5 14.5 
 




7869.7 6374.8 4249.2 1088.4 260 5.9 
 
8861.5 7869.7 0.00 0.22 
female 30 Rat_21 LLOQ 48829 34617 20031 5021.6 2354.4 25.1 2.9 55081 48829 0.25 0.75 
 
Rat_23 LLOQ 39603 35316 28252 13498 4608.7 3402.4 5.4 112473 39603 0.25 1.91 
 
Rat_24 LLOQ 47699 34496 18881 4884.8 2190.4 30.9 LLOQ 52982 47699 0.25 0.77 
 








5032.2 442.7 5110.8 4933.8 1351.4 1948.2 1.8 33758 5032.2 0.00 0.67 
female 100 Rat_25 LLOQ 85304 94121 63234 36145 7437.9 930.8 14.6 190003 94121 0.50 1.12 
 
Rat_26 LLOQ 109550 117250 93617 53711 21022 13037 10.1 415652 117250 0.50 2.35 
 
Rat_27 LLOQ 73801 73574 42074 20727 5212.5 2696.3 4.6 151324 73801 0.25 1.61 
 
Rat_28 LLOQ 110470 108320 49888 26957 7125.6 3279.9 7.3 200324 110470 0.25 1.57 
 








18205 19047 22692 14356 7281.8 5459.4 4.3 119428 19351 0.14 0.51 




Table 4.  Comparison of S3643 Exposure (AUClast  and Cmax)  in Plasma Between Female 











IV AUClast 1 0.76 0.14 
 
Cmax 1 0.91 0.23 
PO AUClast 10 0.53 0.36 
 
AUClast 30 0.92 0.54 
 
AUClast 100 1.31 0.72 
 
Cmax 10 0.46 0.27 
 
Cmax 30 0.89 0.21 
 





Table 5.  Absolute Bioavailability of S3643 in Plasma Following Single IV and Oral 








male PO 10 95.5 26.0 
   30 96.0 36.4 
   100 65.7 16.0 
female PO 10 67.4 43.5 
   30 116.1 56.8 






In Vivo Metabolism of S3643 in Rats 
 
Senomyx Study No. S3643-PK2 
 
Experimental Study Design 
The four male and four female Sprague-Dawley rats were assigned to the study as presented in 













1 S3643 4 PO 
1% methyl 
cellulose
 100 Male 




       
S3643 was administered once for Group 1 and 2 via oral gavage at a dose volume of ~10 mL/kg.  
The dose was based on the most recent body weight. 
 
Sample Collection, Handling, Storage, and Transfer 
Blood samples were collected from a jugular catheter into tubes containing K2EDTA as the 
anticoagulant.  Samples were collected from Groups 1 and 2 at approximately 0, 15, 30 min, 1, 2, 
4, 8, and 24 hours post dose.  The samples were stored on ice for no more than one hour until 
centrifuged at 2 to 7 C. The plasma samples were placed on dry ice prior to storage at 
approximately -70 C.  Samples were protected from direct sunlight during collection and 
processing.  Samples were transferred to the Analytical Department at the Test Facility for 
analysis by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-
QTOF/MS). 
 
Plasma Sample Preparation 
On the day of analysis, the plasma samples were thawed at room temperature (RT).  Plasma (10 
µL) from each animal was pooled together by each time point.  Proteins from plasma samples 
(80 µL) were precipitated by addition of 240 µL of acetonitrile.  After 10 minutes of 
centrifugation (Sorvall Legend XTR, 6,000 rpm, 10 C), 50 µL of the resulting supernatant was 
mixed with 100 µL deionized water.  The solution was analyzed by LC-QTOF/MS. 
 
LC-QTOF/MS Analysis 
The prepared plasma samples were analyzed using an LC-QTOF/MS (Agilent iFunnel 6550A 
MS Q-TOF) equipped with an Agilent 1290 Infinity Binary pump and an Agilent 1290 Infinity 






HPLC pump Agilent 1290 Infinity Binary pump 
Autosampler Agilent 1290 Infinity Autosampler 
Column Zorbax Eclipse Plus C18, 2.1 x 50 mm, 1.8 m 
Mobile Phase A 2 mM Ammonium acetate and 0.1 % formic acid in water 
Mobile Phase B Methanol 
Flow Rate 1.0 mL/min 
Injection Volume 1.0 L 
Column Temperature 40 C 
Gradient 
Time (min)     %B  Valve switch 
0.0        5  1 => 2 
0.2        5 
6.5                         40 
7.5                         95 
8.5                         95 
8.51                         5 
10.0                         5 
Acquisition Time 10.0 min 
S3643 Retention Time ~ 5.79 min 
 
Mass Spectrometric Conditions 
Instrument Agilent iFunnel 6550A MS Q-TOF  
Ionization Source Dual AJS ESI 
Polarity Positive 
Gas Temp (◦C) 275 
Gas Flow (L/min) 13 
Nebulizer (psig) 30 
SheathGasTemp (◦C) 375 
SheathGasFlow (L/min) 12 
VCap (V) 3250 
Nozzle Voltage (V) 0 
Fragmentor (V) 125 
Ref Mass Enabled Enabled 
Ref Nebulizer (psig) 5 
Reference Masses 121.0509, 922.0098 
 
 
Table 6. Phase II Metabolites of S3643 Observed in Rat Plasma 
 








 395.0436 (M+H), 315.0909, 300.0662, 192.0766, 




 521.1337 (M+H), 345.1016, 330.0778, 312.0680, 
222.0872, 207.0626, 189.0522, 124.0210, 93.0568 
2.74 
    a. Retention time using a Zorbax Eclipse Plus C18 column (50 x 2.1 mm, 1.8 μm) and 2 mM ammonium    




Figure 4a.  Proposed Fragmentation of M394 
 
 




Reverse Bacterial Mutation Assay: S3643 
 
Table 7.  Plate Incorporation Assay 
Nucro-Technics Project No. 257958 
 
 S3643  
Colony Counts                    Mean ± SD Lawn 
 mg per plate  
TA98, -S9       
* 0 24 20 18   NL 
* 0 25 19 14 20 ± 4 NL 
0.016 19 11 16 15 ± 4 NL 
0.031 18 15 16 16 ± 2 NL 
0.063 16 23 21 20 ± 4 NL 
0.13 29 22 31 27 ± 5 NL 
0.25 11 22 13 15 ± 6 NL 
0.50 26 13 27 22 ± 8 NL 
1.0 15 25 24 21 ± 6 NL 
2.0 18 22 13 18 ± 5 NL 
*  2-NF, 5 µg        1875 
       2166 
    2069 
    2070 
1825 
1919    
1987 ± 133 NL 
NL 
TA98, +S9       
0 35 38 31 35 ± 4 NL 
0.13 34 31 37 34 ± 3 NL 
0.25 21 30 26 26 ± 5 NL 
0.50 27 43 33 34 ± 8 NL 
1.0 29 25 21 25 ± 4 NL 
2.0 19 11 20 17 ± 5 NL 
B[α]P, 5 µg 425 399 433 419 ± 18 NL 
 
TA100, -S9 
      
* 0 114 108 106   NL 
* 0 114 107 108 110 ± 4 NL 
0.016 112 104 103 106 ± 5 NL 
0.031 123 106 101 110 ± 12 NL 
0.063 106 92 105 101 ± 8 NL 
0.13 106 109 110 108 ± 2 NL 
0.25 111 108 105 108 ± 3 NL 
0.50 108 111 114 111 ± 3 NL 
1.0 83 100 131 105 ± 24 NL 
2.0 120 102 98 107 ± 12 NL 
*  NaAz, 5 µg 1898 1887 1960 1879 ± 204 NL 




      
0 115 102 117 111 ± 8 NL 
0.13 110 106 104 107 ± 3 NL 
0.25               96 100 120 105 ± 13 NL 
0.50               96 108 108 104 ± 7 NL 
1.0 116 121 98 112 ± 12 NL 
2.0 98 108 104 103 ± 5 NL 
       




Table 7. Plate Incorporation Assay (continued) 
Nucro-Technics Project No. 257958 
 
 S3643  
Colony Counts                    Mean ± SD Lawn 
 mg per plate  
 
TA1535, -S9       
* 0 14 15 17   NL 
* 0 19 6 18 15 ± 5 NL 
0.016 19 18 17 18 ± 1 NL 
0.031 15 13 17 15 ± 2 NL 
0.063 18 22 19 20 ± 2 NL 
0.13 13 8 17 13 ± 5 NL 
0.25 11 17 13 14 ± 3 NL 
0.50 13 14 10 12 ± 2 NL 
1.0 16 8 18 14 ± 5 NL 
2.0 6 12 7 8 ± 3 NL 
*  NaAz, 5 µg 1953 1975 2091 1914 ± 113 NL 
 1828 1799 1835   NL 
    TA1535, +S9       
0 18 13 18 16 ± 3 NL 
0.13 12 12 19 14 ± 4 NL 
0.25 16 15 17 16 ± 1 NL 
0.50 14 12 12 13 ± 1 NL 
1.0 19 15 17 17 ± 2 NL 
2.0 8 12 4 8 ± 4 NL 
CP, 100 µg 129 114 137 127 ± 12 NL 
 
TA1537, -S9 
      
* 0 10 12 15   NL 
* 0 9 10 10 11 ± 2 NL 
0.016 11 6 7 8 ± 3 NL 
0.031 6 7 7 7 ± 1 NL 
0.063 9 13 9 10 ± 2 NL 
0.13 12 9 11 11 ± 2 NL 
0.25 10 10 12 11 ± 1 NL 
0.50 4 18 8 10 ± 7 NL 
1.0 2 9 5 5 ± 4 NL 
2.0 2 5 2 3 ± 2 NL 
*  9-AA, 100 µg 1259 1233 1315 1541 ± 312 NL 
 1974 1725 1737   NL 
       
TA1537, +S9 
0 29 20 15 19 ± 3 NL 
0.13 19 14 12 15 ± 4 NL 
0.25 21 16 17 18 ± 3 NL 
0.50  13 16 13 14 ± 2 NL 
1.0 9 8 8 8 ± 1 NL 
2.0 5 3 8 4 ± 1 NL 




Table 7. Plate Incorporation Assay (continued) 
Nucro-Technics Project No. 257958 
 
 S3643  
Colony Counts                    Mean ± SD Lawn 
 mg per plate  
WP2 uvrA, -S9       
0 31 33 31 32 ± 1 NL 
0.25 33 31 24 29 ± 5 NL 
0.50 33 23 36 31 ± 7 NL 
1.0 23 21 25 23 ± 2 NL 
2.0 32 28 31 30 ± 2 NL 
5.0 20 25 29 25 ± 5 NL 
MMS, 1 µl 407 423 396 409 ± 14 NL 
WP2 uvrA, +S9       
0 49 46 40 45 ± 5 NL 
0.25 39 45 39 41 ± 3 NL 
0.50 47 38 37 41 ± 6 NL 
1.0 48 46 43 46 ± 3 NL 
2.0 45 34 51 43 ± 9 NL 
5.0 44 42 25 37 ± 10 NL 




Note:    
9-AA , 9-aminoacridine   NL , Normal Background Lawn    
2-AMA , 2-aminoanthracene   SR , Slight Reduction of Lawn    
2-NF , 2-nitrofluorene   MR, Moderate Reduction of Lawn    
NaAz , sodium azide   ER, Extreme Reduction of Lawn    
B[  ]P , benzo[ ]pyrene       
CP , cyclophosphamide       
MMS, methyl methanesulfonate       
*, A portion of the experiment was repeated 
thus the mean of all six negative and positive 
controls was reported 
      





Table 8. Preincubation Assay 
Nucro-Technics Project No. 257958 
 
S3643  
Colony Counts                    Mean ± SD Lawn 
mg per plate  
TA98, -S9       
0 18 21 29 23 ± 6 NL 
0.13 26 23 19 23 ± 4 NL 
0.25 25 17 14 19 ± 6 NL 
0.50 19 20 24 21 ± 3 NL 
1.0 11 15 22 16 ± 6 NL 
2.0 5    6 5 5 ± 1 NL 
2-NF, 5 µg 1313 1496 1300 1370 ± 110 NL 
TA98, +S9        
0 32 33 26 30 ± 4 NL 
0.031 24 27 39 30 ± 8 NL 
0.063 26 28 23 26 ± 3 NL 
0.13 24 29 23 25 ± 3 NL 
0.25 28 21 30 26 ± 5 NL 
0.50 14 17 26 19 ± 6 NL 
1.0 6 5 9 7 ± 2 NL 
B[α]P, 5 µg 437 476 475 463 ± 22 NL 
 
TA100, -S9 
      
0 126 122 136 128 ± 7 NL 
0.13 126 123 135 128 ± 6 NL 
0.25 140 123 116 126 ± 12 NL 
0.50 127 121 122 123 ± 3 NL 
1.0 95 100 117 104 ± 12 NL 
2.0 122 109 119 117 ± 7 NL 
NaAz, 5 µg 1896 1874 1881 1884 ± 11 NL 
TA100, +S9       
0 162 148 147 152 ± 8 NL 
0.031 152 143 144 146 ± 5 NL 
0.063 141 150 137 143 ± 7 NL 
0.13 145 131 158 145 ± 14 NL 
0.25 153 132 137 141 ± 11 NL 
0.50 147 127 150 141 ± 13 NL 
1.0 128 139 122 130 ± 9 NL 






Table 8. Preincubation Assay (continued) 
Nucro-Technics Project No. 257958 
 
 S3643  
Colony Counts                     Mean ± SD Lawn 
 mg per plate  
TA1535, -S9       
0 14 18 15 16 ± 2 NL 
0.13 15     9 20 15 ± 6 NL 
0.25 20 15 12 16 ± 4 NL 
0.50 10 23 16 16 ± 7 NL 
1.0 10 16 16 14 ± 3 NL 
2.0 3    7 6 5 ± 2 NL 
NaAz, 5 µg 1628 1848 1563 1680 ± 149 NL 
TA1535, +S9       
0 20 13 21 18 ± 4 NL 
0.031 16 12 9 12 ± 4 NL 
0.063 18 19 14 17 ± 3 NL 
0.13 8 19 17 15 ± 6 NL 
0.25 17 19 15 17 ± 2 NL 
0.50 13 11 13 12 ± 1 NL 
1.0 11 11 10 11 ± 1 NL 
CP, 100 µg 203 189 190 194 ± 8 NL 
 
TA1537, -S9 
      
0 9 7 9 8 ± 1 NL 
0.063 15 8 5 9 ± 5 NL 
0.13 5 6 7 6 ± 1 NL 
0.25 14 5 10 10 ± 5 NL 
0.50 6 6 4 5 ± 1 NL 
1.0 7 5 5 6 ± 1 NL 
2.0 0 2 2 1 ± 1 NL 
9-AA, 100 µg 937 1091 983 1004 ± 79 NL 
TA1537, +S9       
0 22 11 9 14 ± 7 NL 
0.031 17 13 11 14 ± 3 NL 
0.063 15 16 11 14 ± 3 NL 
0.13 11 18 12 14 ± 4 NL 
0.25 10    5 9 8 ± 3 NL 
0.50 14    5 11 10 ± 5 NL 
1.0 7    8 5 7 ± 2 NL 






Table 8. Preincubation Assay (continued) 
Nucro-Technics Project No. 257958 
 
 S3643  
Colony Counts                    Mean ± SD Lawn 
 mg per plate  
WP2 uvrA, -S9       
0 10 10 13 11 ± 2 NL 
0.25 10 17 12 13 ± 4 NL 
0.50        9    9 13 10 ± 2 NL 
1.0 12 13 13 13 ± 1 NL 
2.0 10 12 10 11 ± 1 NL 
5.0 12   9 15 12 ± 3 NL 
MMS, 1 µl 1062 1141 1064 1089 ± 45 NL 
WP2 uvrA, +S9       
0 17 21 18 19 ± 2 NL 
0.25 26 26 19 24 ± 4 NL 
0.50 20 19 26 22 ± 4 NL 
1.0 11 15 21 16 ± 5 NL 
2.0 18 13 18 16 ± 3 NL 
5.0 20 23 26 23 ± 3 NL 




Note:    
9-AA , 9-aminoacridine   NL , Normal Background Lawn    
2-AMA , 2-aminoanthracene   SR , Slight Reduction of Lawn    
2-NF , 2-nitrofluorene   MR, Moderate Reduction of Lawn    
NaAz , sodium azide   ER, Extreme Reduction of Lawn    
B[  ]P , benzo[ ]pyrene       
CP , cyclophosphamide       
MMS, methyl methanesulfonate       
       





In Vitro Chromosome Aberration Test of S3643 in Human Lymphocytes 
 
Table 9.   Relative Cell Growth 
Nucro-Technics Project No. 257957 
   
______________________________________________                     _______________________________________________         _______________________________________________ 
RCG = Relative Cell Growth 
 
  
3 hrs -S9 
S3643 Cells Mean 
 (mg/mL)      (x 10
6
)       (x 10
6
)

























































































20 hrs -S9 












































Table 10.   Relative Mitotic Index 
Nucro-Technics Project No. 257957 
   
 


























































    
3 hrs +S9 
S3643 M/500 







































20 hrs -S9 
S3643 M/500 









































Table  11-1.  Structural Chromosome Aberrations, 3 Hours , -S9 






















     tr qr cr id ci 














 100 1        1         1 1 
0 100   0 0 
    0.5 0.5 
 100     1          0 0 
0.13 100     1        1 1 1 
    0.5 0.5 
 100         1         1 1 
0.25 100     1  0 0 
    0.5 0.5 
 100     1          0 0 
0.5 100         2 2 2 
    1.0 1.0 
  50     1        4        1        10 10 
MMC 
(0.2 µg/mL) 
100     3        5 
 
1 1 7 7 
       8.5 8.5 
                                     




Table  11-2.  Structural Chromosome Aberrations, 3 Hours , +S9 












  Simple 
 





    tr qr cr id ci 
 Chromosome Type 
 
        Simple Complex 
 










100 1        1         1 1 
0      100 1        1 1 1 
          1.0 1.0 
100 2       2         2 2 
         0.063 100 1  0 0 
          1.0 1.0 
100 1       1         1 1 
0.13      100 2       1 1 1 
             1.0 1.0 
100 3       2    1     3 3 
0.25      100 4       3  3 3 
           3.0 3.0 
43 4       4       1   1     14 14 
CP 
(10 µg/mL) 
      46 4       5   
 
1 1 15 13 
      14.6 13.5 
                                         




Table  11-3.  Structural Chromosome Aberrations, 20 Hours , -S9 
Nucro-Technics Project No. 257957 
 
 
















     tr qr cr id ci 














                             100 1       1         1 1 
0     100 2       1 1 1 
   1.0 1.0 
                             100 1       1         1 1 
       0.063 100 2  1 1 1 
    1.0 1.0 
                              100 1          0 0 
0.13      100 2       2 2 2 
   1.0 1.0 
                              100 1          0 0 
0.25     100 3       3 3 3 
   1.5 1.5 
50 2       6    1     14 12 
MMC 
(0.1 µg/mL) 
     50 1       4       1 1 12 10 
     13.0 11.0 
                               




Table  11-4.  Numerical Chromosome Aberrations 
Nucro-Technics Project No. 257957 
   
__________________________________________     
 















 100  0  
0   0.0 
 100 0  
 100  0  
0.13   0.0 
 100 0  
 100  0  
0.25   0.0 
 100 0  
 100  0  
0.50   0.0 
 100 0  
 











 100  0  
0   0.0 
 100 0  
 100  0  
0.063   0.0 
 100 0  
 100  0  
0.13   0.0 
 100 0  
 100  0  
0.25   0.0 
 101 0  
 











 100  0  
0   0.0 
 100 0  
 100  0  
0.031   0.0 
 100 0  
 100  0  
0.063   0.0 
 100 0  
 100  0  
0.13   0.0 




In Vitro Micronucleus Test of S3643 in Chinese Hamster Ovary Cells 
  
Table  12-1.  Cytostasis 
Nucro-Technics Project No. 257956 
 
  
Nuclei Frequency = Number of mono-, bi- and multi-nucleated cells 
CBPI = Cytokinesis-Block Proliferation Index = (mononucleated cells + 2X binucleated cells + 3X multinucleated cells) / total cells 
CYT (%) = % Cytostasis = 100-100{(CBPIT-1)/(CBPIC-1)} where T = Test Substance and C = Negative Control 
"**" Cells were altered in morphology and were only single binucleated cells 
"*" Cells were not harvested due to cell death 
3 Hours -S9 
Nuclei 









 75 393 32 500  
0     1.93 0 
 62 401 37 500  
 55 417 28 500  
100     1.93 1 
 83 380 37 500  
 64 417 19 500  
200     1.93 0 
 59 405 36 500  
 168 321 11 500  
300     1.70 25 
 161 318 21 500  
 455 45 0 500  
450     1.07 93 
 476 24 0 500  
 - - - -   
*600     - - 
 - - - -   
 











 87 391 22 500  
0     1.89 0 
 71 407 22 500  
 89 382 29 500  
50     1.89 -1 
 77 395 28 500  
 76 389 35 500  
100     1.90 -2 
 78 399 23 500  
 197 295 8 500  
200     1.63 29 
 187 304 9 500  
 465 35 0 500  
300     1.08 91 
 454 46 0 500  
 - - - -   
**450     - - 
 - - - -   
 - - - -   
*600     - - 
 - - - -   
 











 84 900 16 1000  
0     1.93 0 
 95 887 18 1000  
 187 801 12 1000  
16     1.83 10 
 175 811 14 1000  
 308 668 24 1000  
31     1.72 22 
 282 708 11 1001  
 571 429 0 1000  
63     1.46 50 
 505 495 0 1000  
 873 127 0 1000  
80     1.13 87 
 877 123 0 1000  
 925 75 0 1000  
130     1.06 93 




Table  12-2.  Micronuclei Incidence 
Nucro-Technics Project No. 257956 
   
MN = Micronuclei 
BN = Binucleated Cell(s) 
Number of BN with MN = Refers to the number of binucleated cells with 1, 2 or 3+ micronuclei 
 
MN per BN=  ((#BN with one MN)+2 (#BN with two MN)+3 (# of BN with three or more   MN))/(Total BN analyzed) 
 
% BN with MN=  ((# of BN with MN)/(Total BN))  X  100 
3 Hours -S9 
Number of BN 
Dose   with MN   
(µg/mL) 






MN per  % BN 
BN with MN 
 10 0 1 1000  
0     0.011 1.0 
 8 0 0 1000  
 7 2 0 1000  
100     0.014 1.2 
 12 2 0 1000  
 14 0 0 1000  
200     0.015 1.4 
 13 1 0 1000  
 7 1 0 1000  
300     0.013 1.1 


















3 Hours +S9 
Number of BN 
Dose   with MN   
(µg/mL) 






MN per  % BN 
BN with MN 
 12 0 0 1000  
0     0.018 1.6 
 17 2 1 1000  
 10 2 0 1000  
50     0.014 1.2 
 10 2 0 1000  
 7 2 0 1000  
100     0.020 1.7 
 21 2 1 1000  
 17 2 1 1000  
200     0.025 2.1 


















19 Hours -S9 
Number of BN 
Dose   with MN   
(µg/mL) 






MN per  % BN 
BN with MN 
 8 0 0 1000  
0     0.011 1.1 
 14 0 0 1000  
 17 0 0 1000  
16     0.014 1.4 
 9 1 0 1000  
 8 2 0 1000  
31     0.014 1.3 
 16 0 0 1000  
 18 0 0 1000  
63     0.020 1.9 




















28-Day Range Finding Toxicology Study of S3643 in Sprague-Dawley Rats 
  
Study Design 




(SD)] rats were administered 
the test article at dose levels of 10, 30, and 100 mg/kg bw/day.  One additional group of five 
animals/sex served as the control and received untreated (vehicle) diet.  The vehicle or test article 
diet was available ad libitum for 28 consecutive days.  Body weights were measured and 
recorded on Days - 1, 4, 7, 11, 14, 21, and 28.  Food consumption was measured and recorded on 
Days 4, 7, 11, 14, 21, and 28. Compound consumption was calculated at the same intervals as 
food consumption.  Ophthalmoscopic examinations were conducted pretest and prior to the 
terminal necropsy.  Blood and urine samples for clinical pathology evaluations were collected 
from all animals prior to the terminal necropsy.  At study termination, necropsy examinations 
were performed, organ weights were recorded, and only the liver was microscopically examined 
for animals at 0 and 100 mg/kg bw/day. 


















    1, 4            2, 3    
 
Adrenal gland X X   
Aorta   X   
Bone with bone marrow, femur  X   
Bone with bone marrow, sternum  X   
Bone marrow smear  X   
Brain (cerebrum, midbrain, cerebellum, 
medulla/pons) 
X X   
Epididymis X X   
Esophagus  X   
Eye (with optic nerve)  X   
GALT
 
(Gut-Associated Lymphoid Tissue)  X   
Heart X X   
Joint, tibiofemoral  X   
Kidney X X   
Lacrimal gland, exorbital  X   
Large intestine, cecum  X   
Large intestine, colon  X   
Large intestine, rectum  X   
Larynx  X   
Liver X X X  
Lung with bronchi X X   




















    1, 4            2, 3    
 
Lymph node, mesenteric  X   
Mammary gland (process females only)  X   
Nerve, sciatic  X   
Ovary with Oviducts X X   
Pancreas  X   
Pituitary X X   
Prostate X X   
Salivary gland, mandibular X X   
Salivary gland, parotid  X   
Salivary gland, sublingual  X   
Seminal vesicles  X   
Skeletal muscle, biceps femoris  X   
Skin  X   
Small intestine, duodenum  X   
Small intestine, ileum  X   
Small intestine, jejunum  X   
Spinal cord, cervical  X   
Spinal cord, lumbar  X   
Spinal cord, thoracic  X   
Spleen X X   
Stomach, glandular  X   
Stomach, nonglandular  X   
Target Organs
 
 X X X 
Testis X X   
Thymus X X   
Thyroid gland (with parathyroid) X X   
Tongue  X   
Trachea  X   
Ureters  X   
Urinary bladder  X   
Uterus with cervix X X   
Vagina  X   
Gross lesions  X   
Tissue masses with regional lymph node
 






Table 14-1.  Summary of Body Weights - Male 
MPI Research Study No. 1646-015 
S3643: A 4-Week Dietary Administration Toxicity Study in Rats (non-GLP) 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Day) Mean SD N Mean SD N Mean SD N Mean SD N 









































1 186.0 8.25 5 187.4 6.88 5 187.0 11.60 5 188.4 8.38 5 
 4 216.2 8.70 5 217.0 9.77 5 217.4 13.70 5 216.8 11.95 5 
 7 239.2 10.43 5 240.4 12.20 5 238.2 15.77 5 241.2 11.90 5 
 11 266.8 14.18 5 275.0 19.43 5 264.4 15.65 5 272.6 13.94 5 
 14 285.8 14.53 5 291.4 18.64 5 284.2 20.13 5 291.4 16.33 5 
 21 332.6 16.47 5 338.8 27.64 5 330.8 26.68 5 335.4 17.64 5 
 28 358.8 24.18 5 368.0 33.20 5 357.0 25.16 5 361.0 18.28 5 
              
 
Table 14-2.  Summary of Body Weights – Female 
MPI Research Study No. 1646-015 
S3643: A 4-Week Dietary Administration Toxicity Study in Rats (non-GLP) 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Day) Mean SD N Mean SD N Mean SD N Mean SD N 









































 1 167.0 7.84 5 166.0 5.83 5 164.8 7.60 5 167.2 5.93 5 
 4 183.0 8.66 5 180.6 6.31 5 177.8 9.44 5 181.2 5.02 5 
 7 191.6 12.10 5 187.6 4.77 5 186.2 8.67 5 185.6 5.22 5 
 11 201.4 12.76 5 196.4 5.59 5 196.8 10.55 5 195.8 5.12 5 
 14 205.8 13.39 5 201.4 8.71 5 199.2 11.21 5 199.4 8.20 5 
 21 226.4 14.33 5 220.8 9.23 5 218.4 11.55 5 215.6 7.33 5 
 28 231.4 15.19 5 228.2 10.11 5 219.8 8.98 5 220.6 6.19 5 
              
 
  N – Number of measures 
SD – Standard Deviation  
40 
 
Table 15-1.  Summary of Food Consumption - Male 
MPI Research Study No. 1646-015 
S3643: A 4-Week Dietary Administration Toxicity Study in Rats (non-GLP) 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 










































 7 24.20 2.545 5 24.47 1.924 5 22.60 2.229 5 24.13 1.556 5 
 11 25.40 3.338 5 25.15 1.755 5 24.05 3.099 5 24.75 1.591 5 
 14 24.67 1.563 5 25.20 1.909 5 23.40 2.253 5 24.67 1.130 5 
 21 25.34 1.889 5 25.20 2.300 5 24.09 2.074 5 24.57 1.208 5 
 28 25.09 2.685 5 25.63 2.549 5 23.89 1.251 5 24.09 2.173 5 





Table 15-2.  Summary of Food Consumption - Female 
MPI Research Study No. 1646-015 
S3643: A 4-Week Dietary Administration Toxicity Study in Rats (non-GLP) 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 










































 7 16.73 1.362 5 16.60 0.863 5 16.00 1.546 5 16.33 2.906 5 
 11 17.15 1.040 5 16.40 1.537 5 15.85 1.055 5 15.80 1.165 5 
 14 16.87 0.901 5 17.20 1.980 5 15.73 1.090 5 16.93 3.227 5 
 21 17.69 1.197 5 17.00 1.781 5 17.23 1.123 5 16.31 0.950 5 
 28 17.06 1.154 5 17.00 1.857 5 15.49 0.831 5 15.34 0.884 5 
              
 
  N – Number of measures 





Table 16-1.  Summary of Hematology Values – Male  
MPI Research Study No. 1646-015 
S3643: A 4-Week Dietary Administration Toxicity Study in Rats (non-GLP) 
 





























Leukocytes              





























Hemoglobin              
g/dL Terminal 16.82 1.031 5 15.84 0.434 5 16.14 0.493 5 16.16 0.662 5 
Hematocrit              
% Terminal 56.62 4.717 5 52.66 1.324 5 53.98 1.551 5 53.86 1.705 5 
MCV              
fL Terminal 63.32 2.129 5 62.82 2.572 5 65.68 3.268 5 64.24 1.119 5 
MCH              
pg Terminal 18.84 0.532 5 18.90 0.667 5 19.60 0.604 5 19.30 0.557 5 
MCHC              
g/dL Terminal 29.76 0.760 5 30.12 0.687 5 29.88 0.576 5 30.02 0.559 5 
              
 
  N – Number of measures 
SD – Standard Deviation 
  a.







Table 16-1.  Summary of Hematology Values – Male (continued) 
MPI Research Study No. 1646-015 































































































































































































































































              
 
  N – Number of measures 





Table 16-2.  Summary of Hematology Values – Female 
MPI Research Study No. 1646-015 


























































































             
g/dL Terminal 16.48 0.602 5 16.42 0.918 5 16.10 0.671 5 16.60 0.946 5 
Hematocrit 
             
% Terminal 53.20 1.783 5 52.44 3.331 5 52.32 2.386 5 53.14 2.640 5 
MCV              
fL Terminal 61.36 1.524 5 60.10 1.079 5 61.32 1.452 5 61.26 2.485 5 
MCH 
             
pg Terminal 18.98 0.421 5 18.80 0.292 5 18.82 0.476 5 19.12 0.421 5 
MCHC 
             
g/dL Terminal 30.94 0.623 5 31.32 0.669 5 30.74 0.658 5 31.26 0.744 5 
              
 
  N – Number of measures 




Table 16-2.  Summary of Hematology Values – Female (continued) 
MPI Research Study No. 1646-015 


































             
103/µL Terminal 1075.8 89.28 5 1222.4 148.83 5 1196.6 250.11 5 1191.6 108.54 5 
Absolute Reticulocytes 
             
103/µL Terminal 162.28 19.416 5 167.84 29.928 5 172.82 29.914 5 187.52 29.635 5 
Neutrophils 
             






























             
103/µL Terminal 0.230 0.0846 5 0.224 0.0439 5 0.220 0.0930 5 0.244 0.1038 5 
Eosinophils 
             
103/µL Terminal 0.116 0.0767 5 0.084 0.0251 5 0.076 0.0270 5 0.124 0.0358 5 
Basophils 
             
103/µL Terminal 0.068 0.0192 5 0.094 0.0195 5 0.072 0.0179 5 0.088 0.0370 5 




























              
 
  N – Number of measures 
SD – Standard Deviation 
a





Table 17-1.  Summary of Coagulation Values – Male 
MPI Research Study No. 1646-015 



























































































            
 
 
Table 17-2.  Summary of Coagulation Values – Female 
MPI Research Study No. 1646-015 





























































Prothrombin Time  
sec 
 

























              
 
  N – Number of measures 
SD – Standard Deviation 
46 
 
Table 18-1.  Summary of Clinical Chemistry Values – Male 
MPI Research Study No. 1646-015 





































































































































































































































              
 
  N – Number of measures 





Table 18-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-015 































































AST              
U/L Terminal 132.2 137.09 5 72.8 7.89 5 70.6 7.23 5 72.8 4.27 5 
ALT              
U/L Terminal 78.0 83.26 5 31.8 6.02 5 31.4 6.35 5 29.2 1.30 5 
Urea Nitrogen              
mg/dL Terminal 16.8 2.77 5 14.0 1.58 5 16.4 3.21 5 15.4 2.70 5 
Creatinine              
mg/dL Terminal 0.38 0.045 5 0.34 0.055 5 0.36 0.055 5 0.34 0.055 5 
Total Protein              
g/dL Terminal 6.48 0.438 5 6.40 0.367 5 6.20 0.158 5 6.60 0.374 5 
Albumin              
g/dL Terminal 3.44 0.230 5 3.34 0.182 5 3.34 0.089 5 3.50 0.141 5 
              
 
  N – Number of measures 
SD – Standard Deviation 
#





Table 18-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-015 












































































































































































              
 
  N – Number of measures 
SD – Standard Deviation 
#






Table 18-2.  Summary of Clinical Chemistry Values – Female 
MPI Research Study No. 1646-015 

































Sodium              
mEq/L Terminal 143.0 0.71 5 144.6 1.52 5 143.2 1.64 5 143.2 1.30 5 
Potassium              
mEq/L Terminal 7.64 0.404 5 7.06 0.673 5 8.10 1.488 5 7.78 1.110 5 
Chloride 
             
mEq/L Terminal 101.6 1.67 5 100.6 1.95 5 102.0 1.00 5 100.6 1.14 5 
Calcium 
             
mg/dL Terminal 11.88 0.205 5 11.66 0.573 5 11.80 0.648 5 12.28 0.512 5 
Phosphorus 
             






























             
mg/dL Terminal 0.14 0.055 5 0.12 0.045 5 0.10 0.000 5 0.12 0.045 5 
              
 
  N – Number of measures 
SD – Standard Deviation 
a





Table 18-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-015 





































































































































































































































              
 
  N – Number of measures 






Table 18-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-015 


































             
g/dL Terminal 3.18 0.217 5 3.30 0.292 5 3.16 0.251 5 3.30 0.274 5 
Albumin/Globulin Ratio 
             
 Terminal 1.16 0.055 5 1.10 0.071 5 1.16 0.055 5 1.16 0.055 5 
Triglyceride 
             
mg/dL Terminal 32.0 9.87 5 31.2 5.22 5 33.4 8.91 5 35.4 8.99 5 
Cholesterol 
             





























              
 
  N – Number of measures 
SD – Standard Deviation 
a





Table 19-1.  Summary of Urinalysis Values – Male 
MPI Research Study No. 1646-015 


































             
mL Terminal 3.80 1.483 5 4.20 2.515 5 3.70 4.932 5 8.50 4.093 5 



























             
 Terminal 6.70 0.274 5 6.80 0.274 5 7.10 0.822 5 6.80 0.274 5 
              
 
 
Table 19-2.  Summary of Urinalysis Values – Female 
MPI Research Study No. 1646-015 

















































































































              
   
  N – Number of measures                          NA – Not applicable/not available               
a
 Significantly different from control (p<0.05) 
SD – Standard Deviation 
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Table 20-1.  Summary of Macroscopic Observations – Male 
MPI Research Study No. 1646-015 










Number of Animals Examined  5 5 5 5 
all tissues 
























 - mild 0 1 0 0 
 - moderate 0 1 0 0 
       
Table 20-2.  Summary of Macroscopic Observations – Female 
MPI Research Study No. 1646-015 










Number of Animals Examined  5 5 5 5 
all tissues 






















   enlarged - mild 0 0 1 0 




Table 21-1.  Summary of Organ Weights – Male 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 







Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 







Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 











































            



























Kidneys/BrWt             
ratio 1.5462 0.1432 5 1.6278 0.1570 5 1.6040 0.0971 5 1.6533 0.0849 5 
Liver             
g 10.971 0.822 5 12.319 1.237 5 11.532 2.099 5 12.486 1.323 5 
Liver/BWt             
% 3.2892 0.1857 5 3.6084 0.3480 5 3.4431 0.4042 5 3.7390 0.2455 5 
Liver/BrWt             
ratio 5.6922 0.4320 5 6.3251 0.5992 5 5.9716 0.9840 5 6.3410 0.4529 5 
             
 
  N – Number of measures 
SD – Standard Deviation 
a





Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 





Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-1.  Summary of Organ Weights – Male (continued) 
MPI Research Study No. 1646-015 











































            
g 0.585 0.147 5 0.604 0.122 5 0.525 0.083 5 0.533 0.108 5 
Thymus/BWt             
% 0.1745 0.0394 5 0.1752 0.0231 5 0.1595 0.0337 5 0.1596 0.0297 5 
Thymus/BrWt             
















































































             
  N – Number of measures 
SD – Standard Deviation 
a






Table 21-2.  Summary of Organ Weights – Female 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 







































































































































































































            
 
  N – Number of measures 






Table 21-2.  Summary of Organ Weights – Female (continued) 
MPI Research Study No. 1646-015 

























































































































            
 
  N – Number of measures 





Table 22-1.  Summary of Microscopic Observations – Male 
MPI Research Study No. 1646-015 





Observation Severity   
Number of Animals Examined  5 5 
liver  (5) (5) 
infiltration, mononuclear cell - minimal 5 5 
    
 
 ( ) – Number observed 
 
 
Table 22-2.  Summary of Microscopic Observations – Female 
MPI Research Study No. 1646-015 





Observation Severity   
Number of Animals Examined  5 5 
liver  (5) (5) 
infiltration, mononuclear cell - minimal 5 5 
necrosis, focal - minimal 1 0 
vacuolation, focal - minimal 0 1 
vacuolation, periportal - minimal 1 0 
    
 
 ( ) – Number observed 
69 
 
90-Day Subchronic Toxicology Study of S3643 in Sprague-Dawley Rats 
  
Study Design 





(SD)] rats at dose levels of 0 (control), 10, 30, and 100 mg/kg/day.  Additionally, one 
control group of three animals/sex and three treated groups of six animals/sex/group served as 
toxicokinetic (TK) animals and received the vehicle or test article diet in the same manner as the 
main study groups at respective dose levels of 0, 10, 30, and 100 mg/kg/day.  The vehicle or test 
article diet was available ad libitum for 13 weeks.  Samples for hematology and clinical 
chemistry evaluations were collected from all the main study animals on Days 14 and 45, and 
again prior to termination.  Urinalysis and samples for coagulation evaluations were collected 
prior to termination only.  
Sample Collection for Toxicokinetic Analysis 
Blood samples (approximately 0.5 mL) were collected from the TK animals via the sublingual 
vein for determination of the plasma concentrations of S3643. Samples were collected from 1 
cohort of 3 animals/sex (control animals) at 1 hour post the start of the dark cycle on Days 7 and 
90. Samples were collected from 2 cohorts of 3 animals/sex (treated animals) at 1, 3, 6, 12, and 
24 hours post the start of the dark cycle (18:00) on Days 7 and 90. Samples were collected from 
the treated TK animals between 17:00 and 18:00 during the predose collection on Days 7 and 90. 
The animals were not fasted prior to blood collection. Samples were placed in tubes containing 
K2EDTA as an anticoagulant.  The blood samples were placed on wet ice after collection and 
centrifuged under refrigeration. The samples were contained in tightly capped, pre-labeled, 
plastic vials and were stored frozen at -50 to -90C until analyzed. 
 
Sample Preparation for Toxicokinetic Analysis 
Each 25 μL aliquot of sample was mixed with 25 μL of working internal standard (IS, S9767) 
solution (2000 ng/mL). The plate was vortexed, a 400 μL aliquot of methanol was added, and the 
plate was vortexed and centrifuged.  A 50 μL aliquot of the resulting supernatant was transferred 
to a clean plate, 950 μL of water/methanol (55:45, v/v) was added, and the plate was mixed.  A 
50 μL aliquot of the resulting solution was added to a clean autosampler plate and a 600 μL 
aliquot of water/methanol (55:45, v/v) was added, the plate was mixed, centrifuged, and an 
aliquot was injected onto an LC-MS/MS system for analysis. 
 
Analytical Method 
The liquid chromatography system used an ACE 5 C18-PFP column, 2.1 x 50 mm (5 μm particle 
size) with an isocratic flow of 10 mM ammonium acetate in water/methanol/acetonitrile 
(550:225:225, v/v/v) at a flow rate of 450 μL/minute. The analyte (S3643) and internal standard 
(S9767) were detected using an Applied Biosystems/MDS Sciex API 5000 triple quadrupole LC-
MS/MS system equipped with an ESI (TurboIonSpray®) ionization source operated in the 
positive ion mode. The following MRM transitions of the respective [M+H]+ ions were used to 
monitor S3643 and S9767 and may have been slightly modified to optimize system response. 
Actual transitions and retention times were documented in the data. 
 
Compound Transition Monitored Retention Time 
S3643 (analyte) m/z 328.9 → 206 0.8 – 1.1 min 





Table 23-1. Concentration Analysis of S3643 in Plasma of Sprague-Dawley Rats on Day 7 
 
      Time Point (hr) 
      0 1 3 6 12 24 
Sex Dose Group Animal No. Concentration (ng/mL) 





































    6006 
 
123   220   216 
  
 
Mean (M) 50.2 76 201 264 312 173 
  
 
SD 43.7 67 151 40.2 118 53.6 

































    6506   279   338   165 
  
 
Mean (F) 0 210 123 287 185 111 
    SD 0 64 129 266 72 96 
    Mean (M + F) 25.1 143 162 276 248 142 
    SD 39.0 93.8 133 170 112 77 





































    7006   258   1280   96.6 
    Mean (M) 252 489 618 1421 806 281 
  
 
SD 142 637 391 1026 210 350 

































    7506   842   3270   1280 
    Mean (F) 133 689 906 2690 2177 869 
    SD 230 133 804 570.3 196 518 
    Mean (M + F) 192 589 762 2055 1491 575 
    SD 183 426 587 1017 772 510 

































    8006   4550   3870   790 
  
 
Mean (M) 2237 3240 5040 5633 6863 2967 
  
 
SD 2498 1605 1482 2062 2379 1915 

































    8506   2180   4750   1970 
    Mean (F) 829 2890 4289 3800 5606 657 
    SD 1269 1452 4212 2523 4312 1137 
    Mean (M + F) 1533 3065 4665 4717 6235 1812 
    SD 1933 1382 2854 2293 3190 1893 
LLQ = 50 ng/mL 




Table 23-2. Concentration Analysis of S3643 in Plasma of Sprague-Dawley Rats on Day 90 
 
      Time Point (hr) 
      0 1 3 6 12 24 
Sex Dose Group Animal No. Concentration (ng/mL) 





































    6006 
 
462   2090   91.7 
  
 
Mean (M) 383 512 516 1174 745 266 
  
 
SD 149 178 322 798 294 169 

































    6506   247   139   103 
  
 
Mean (F) 144 422 450 518 304 57 
    SD 149 213 201 617 148 52 
    Mean (M + F) 264 467 483 846 525 161 
    SD 187 182 243 732 319 160 





































    7006   938   2770   263 
    Mean (M) 849 1669 1819 2513 2150 172 
  
 
SD 411 1040 1881 1770 520 149 

































    7506   1420   2440   1680 
    Mean (F) 711 1055 2627 3800 3563 629 
    SD 224 478 2254 1488.4 1100 910 
    Mean (M + F) 780 1362 2223 3157 2857 400 
    SD 306 798 1908 1623 1092 635 

































    8006   5170   4260   9590 
  
 
Mean (M) 9173 5870 13983 9520 13523 5848 
  
 
SD 2907 681 3871 4781 5844 5012 

































    8506   7150   9330   1880 
    Mean (F) 1445 3209 6784 6910 6957.333 651 
    SD 2186 3444 5593 4525 7972 1065 
    Mean (M + F) 5309 4540 10384 8215 10240 3249 
    SD 4818 2656 5836 4402 7213 4313 
 
LLQ = 50 ng/mL 






















    1, 4            2, 3    
 
Adrenal gland X X X  
Aorta   X X  
Bone with bone marrow, femur  X X  
Bone with bone marrow, sternum  X X  
Bone marrow smear  X X  
Brain (cerebrum, midbrain, cerebellum, 
medulla/pons) 
X X X  
Epididymis X X X  
Esophagus  X X  
Eye (with optic nerve)  X X  
GALT
 
(Gut-Associated Lymphoid Tissue)  X X  
Heart X X X  
Joint, tibiofemoral  X X  
Kidney X X X  
Lacrimal gland, exorbital  X X  
Large intestine, cecum  X X  
Large intestine, colon  X X  
Large intestine, rectum  X X  
Larynx  X X  
Liver X X X  
Lung with bronchi X X X  
Lymph node, mandibular  X X  
Lymph node, mesenteric  X X  
Mammary gland (process females only)  X X  
Nerve, sciatic  X X  
Ovary with Oviducts X X X  
Pancreas  X X  
Pituitary X X X  
Prostate X X X  
Salivary gland, mandibular  X X  
Salivary gland, parotid  X X  
Salivary gland, sublingual  X X  
Seminal vesicles X X X  
Skeletal muscle, biceps femoris  X X  
Skin  X X  




















    1, 4            2, 3    
 
Small intestine, ileum  X X  
Small intestine, jejunum  X X  
Spinal cord, cervical  X X  
Spinal cord, lumbar  X X  
Spinal cord, thoracic  X X  
Spleen X X X  
Stomach, glandular  X X  
Stomach, nonglandular  X X  
Target Organs
 
 X X X 
Testis X X X  
Thymus X X X  
Thyroid gland (with parathyroid) X X X  
Tongue  X X  
Trachea  X X  
Ureters  X X  
Urinary bladder  X X  
Uterus with cervix X X X  
Vagina  X X  
Gross lesions  X X X 
Tissue masses with regional lymph node
 




Table 25-1.  Summary of Body Weights - Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 










































 1 306.2 21.26 20 306.3 18.92 20 308.7 20.93 20 301.6 19.31 20 
 2 316.3 23.24 20 318.2 24.08 20 317.9 23.43 20 316.4 20.84 20 
 3 375.7 27.60 20 377.0 28.79 20 377.0 31.05 20 374.9 30.66 20 
 4 402.3 41.62 20 413.8 35.28 20 411.5 34.37 20 409.9 34.92 20 
 5 433.2 36.68 20 441.2 39.48 20 437.9 43.24 20 436.8 37.66 20 
 6 460.7 39.03 20 464.4 42.40 20 463.9 46.72 20 460.7 41.13 20 
 7 477.4 40.27 20 477.6 43.36 20 480.7 46.72 20 476.5 41.92 20 
 8 502.6 43.11 20 502.3 48.32 20 502.9 49.49 20 495.5 43.15 20 
 9 518.9 45.07 20 518.9 50.41 20 519.5 54.50 20 515.2 45.33 20 
 10 536.9 47.78 20 539.1 51.77 20 535.5 55.50 20 533.3 47.38 20 
 11 542.0 48.25 20 549.2 55.77 20 539.9 55.33 20 535.5 53.52 20 
 12 557.3 51.10 20 562.4 59.37 20 553.9 58.08 20 545.9 52.11 20 
 13 555.4 52.78 20 560.5 57.87 20 554.8 60.52 20 547.2 52.68 20 
              
              
 
  N - Number of measures used to calculate mean 






Table 25-2.  Summary of Body Weights - Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Week) Mean SD N Mean SD N Mean SD N Mean SD N 
Body Weight              
g              
 -1 193.4 10.43 20 192.8 14.11 20 194.4 13.72 20 192.0 8.59 20 
 1 212.8 12.69 20 213.8 18.27 20 213.1 15.87 20 203.9 13.11 20 
 2 209.4 14.38 20 210.4 18.20 20 210.6 16.26 20 201.6 10.97 20 
 3 240.5 16.62 20 241.2 19.58 20 238.6 21.24 20 229.1 12.34 20 
 4 249.1 20.51 20 251.2 19.42 20 248.1 23.11 20 237.7 15.07 20 
 5 259.8 20.56 20 257.9 20.01 20 256.5 23.96 20 242.7
a
 17.10 20 
 6 264.3 22.35 20 267.6 23.58 20 265.4 22.89 20 252.3 14.93 20 
 7 271.4 22.88 20 269.1 20.60 20 269.0 25.66 20 252.6
a
 19.74 20 
 8 278.8 24.02 20 279.1 21.59 20 277.1 24.86 20 262.8 17.35 20 
 9 282.4 23.78 20 284.0 21.88 20 280.7 25.09 20 263.9
a
 15.32 20 
 10 287.9 25.16 20 287.6 23.30 20 285.4 25.05 20 269.3
a
 14.48 20 
 11 291.2 24.99 20 293.5 23.26 20 288.0 22.68 20 271.7
a
 14.92 20 
 12 294.0 25.83 20 295.8 24.78 20 294.1 25.86 20 275.8
a
 16.62 20 
 13 293.7 26.27 20 294.0 22.31 20 294.2 24.28 20 275.4
a
 19.17 20 
              
              
 
  N - Number of measures used to calculate mean 
  SD – Standard Deviation 
 
a.






Table 25-3.  Summary of Toxicokinetic Body Weights - Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Week) Mean SD N Mean SD N Mean SD N Mean SD N 







































 1 316.0 18.60 4 307.9 17.13 8 309.4 16.95 8 306.3 20.07 8 
 2 359.3 19.36 4 346.6 20.91 8 349.0 18.28 8 342.8 21.49 8 
 3 395.3 19.52 4 386.5 23.16 8 388.3 20.14 8 378.5 26.05 8 
 4 429.8 23.71 4 423.9 25.82 8 421.5 23.12 8 411.6 30.67 8 
 5 434.8 31.87 4 451.4 29.48 8 448.9 22.78 8 434.5 31.54 8 
 6 474.5 22.04 4 475.1 33.00 8 475.1 26.90 8 455.4 32.19 8 
 7 496.8 24.19 4 496.5 37.05 8 495.4 28.84 8 470.3 33.15 8 
 8 519.3 31.14 4 519.9 38.71 8 515.1 30.23 8 487.5 34.94 8 
 9 533.3 36.85 4 534.1 40.26 8 528.6 32.99 8 500.4 37.21 8 
 10 553.0 42.29 4 556.9 41.69 8 543.0 32.08 8 516.6 38.78 8 
 11 558.8 46.56 4 562.4 45.19 8 546.1 32.25 8 517.4 38.86 8 
 12 563.0 48.72 4 569.8 46.00 8 554.1 35.17 8 521.3 40.37 8 
 13 570.0 55.20 4 578.4 48.51 8 560.9 42.80 8 519.4 54.13 8 
              
              
              
  N - Number of measures used to calculate mean 
  SD – Standard Deviation 






Table 25-4.  Summary of Toxicokinetic Body Weights - Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Week) Mean SD N Mean SD N Mean SD N Mean SD N 







































 1 204.8 16.50 4 215.1 12.60 8 215.1 9.33 8 206.5 8.18 8 
 2 214.0 23.11 4 226.6 11.29 8 233.1 8.77 8 218.1 8.43 8 
 3 231.0 21.02 4 243.4 13.93 8 249.5 16.24 8 226.9 10.70 8 
 4 238.5 22.40 4 249.9 13.43 8 260.9 22.71 8 249.1 9.63 8 
 5 246.8 22.97 4 258.1 14.94 8 268.5 21.75 8 245.5 12.51 8 
 6 255.3 26.42 4 269.3 15.65 8 280.9 25.97 8 253.0 9.90 8 
 7 262.3 26.08 4 275.1 14.09 8 294.1 28.29 8 264.8 13.49 8 
 8 264.5 26.03 4 279.9 16.66 8 305.3 30.76 8 269.4 11.93 8 
 9 270.8 29.07 4 284.4 17.32 8 302.1 27.49 8 269.9 13.03 8 
 10 269.3 16.74 4 293.4 18.33 8 309.0 31.61 8 278.3 12.06 8 
 11 276.3 27.80 4 292.0 19.04 8 307.8 33.13 8 276.5 15.64 8 
 12 280.3 30.25 4 291.1 18.60 8 310.6 27.42 8 278.0 14.91 8 
 13 280.3 31.74 4 292.4 22.88 8 309.1 31.05 8 280.3 13.96 8 
              
              
 
  N - Number of measures used to calculate mean 
  SD – Standard Deviation 






Table 26-1.  Summary of Food Consumption Values - Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Week) Mean SD N Mean SD N Mean SD N Mean SD N 








































 2 22.29 1.550 20 22.81 1.908 20 22.39 1.815 20 22.57 1.531 20 
 3 25.00 1.566 20 25.30 2.012 19 25.41 1.950 20 25.49 2.077 20 
 4 23.44 4.777 20 25.20 2.266 20 25.09 2.585 20 24.91 2.304 20 
 5 25.19 2.212 20 24.69 2.474 20 24.19 3.629 20 24.79 2.049 20 
 6 25.21 2.042 20 25.31 2.380 20 25.26 2.714 20 25.30 2.532 20 
 7 23.81 1.637 20 23.65 2.030 20 23.83 2.193 20 24.19 2.043 20 
 8 25.91 2.006 20 25.69 2.279 20 25.89 2.820 20 25.94 2.134 20 
 9 25.75 2.615 20 25.73 2.468 20 25.47 3.295 20 25.72 2.325 20 
 10 26.17 2.228 20 26.46 2.256 20 25.64 2.715 20 26.71 2.624 20 
 11 26.00 2.280 19 26.39 2.642 20 25.61 2.465 20 25.31 3.424 20 
 12 26.19 2.605 20 26.15 2.606 20 25.29 2.375 20 25.94 2.030 20 
 13 24.49 2.550 20 24.50 2.448 20 23.91 2.665 20 24.02 2.359 20 
              
              
 
  N - Number of measures used to calculate mean 






Table 26-2.  Summary of Food Consumption Values - Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 Study Interval 0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Endpoint (Week) Mean SD N Mean SD N Mean SD N Mean SD N 



























 2 14.61 1.283 20 15.50 1.567 20 15.19 1.130 20 14.41 1.365 20 
 3 18.04 1.621 20 18.21 2.128 20 17.61 1.767 20 17.02 1.566 20 
 4 17.91 3.647 20 18.69 3.175 20 16.72 2.897 20 15.34
a
 1.540 20 
 5 16.36 1.324 20 16.29 1.387 20 15.83 1.449 20 15.00
b
 1.447 20 
 6 16.56 1.452 20 17.33 1.739 20 16.74 1.348 20 16.01 1.006 20 
 7 16.18 1.883 20 16.10 1.359 20 15.79 1.662 20 13.89
b
 1.793 20 
 8 17.27 2.189 20 17.45 1.501 20 17.04 1.459 20 16.19 1.409 20 
 9 16.99 2.281 20 17.01 1.553 20 15.84 1.425 20 15.31
b
 0.767 20 
 10 16.80 3.243 19 17.54 2.135 20 17.11 1.460 20 15.98 1.081 20 
 11 17.27 2.000 20 17.51 1.549 20 16.62 2.151 19 15.82
a
 1.128 20 
 12 16.44 1.568 20 17.29 1.179 20 17.04 1.367 20 15.94 1.144 20 
 13 15.89 1.554 19 16.21 1.175 20 16.29 2.166 20 14.71 1.414 20 
              
              
 
  N - Number of measures used to calculate mean 
  SD – Standard Deviation 
 
a.
 Significantly different from control; (p< 0.05) 
 
b.






Table 27-1.  Summary of Hematology Values – Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Leukocytes              
10³/µL Day 14 9.41 2.421 20 7.87 1.668 20 8.05 2.327 20 8.21 1.808 20 
 Day 45 10.51 2.693 20 10.07 2.429 20 10.69 2.300 20 10.46 1.897 20 

































 Day 45 8.806 0.3530 20 8.546 0.3724 20 8.668 0.3304 20 8.681 0.3610 20 































 Day 45 15.95 0.483 20 15.64 0.669 20 15.80 0.558 20 15.74 0.499 20 































 Day 45 48.55 1.813 20 47.40 2.178 20 47.77 2.055 20 47.77 1.782 20 
 Terminal 50.36 3.905 20 50.08 2.013 20 50.19 2.445 20 49.50 2.107 20 
MCV              
fL Day 14 59.46 2.018 20 60.47 1.949 20 59.76 1.814 20 59.34 1.300 20 
 Day 45 55.16 1.499 20 55.50 1.863 20 55.11 1.423 20 55.04 1.352 20 































 Day 45 18.13 0.427 20 18.31 0.777 20 18.25 0.580 20 18.15 0.521 20 
 Terminal 17.18 0.576 20 17.39 0.713 20 17.28 0.757 20 17.21 0.493 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.
 Significantly different from control; (p< 0.05) 
81 
 
Table 27-1.  Summary of Hematology Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























MCHC              
g/dL Day 14 33.00 0.732 20 33.22 0.870 20 33.15 0.739 20 33.01 0.489 20 
 Day 45 32.87 0.582 20 33.00 0.798 20 33.10 0.772 20 32.95 0.533 20 
 Terminal 30.99 0.421 20 31.05 0.679 20 31.03 0.614 20 31.31 0.438 20 
Platelets              
10³/µL Day 14 916.3 239.69 20 872.0 222.57 20 925.5 206.06 20 879.7 131.70 20 
 Day 45 811.1 160.14 20 777.4 125.46 20 793.9 267.60 20 791.8 202.96 20 
 Terminal 1032.9 100.97 20 1045.3 130.61 20 1125.5 194.08 20 1131.6 162.58 20 
Absolute Reticulocytes              
10³/µL Day 14 264.73 36.622 20 266.29 36.041 20 262.05 45.935 20 280.11 34.246 20 
 Day 45 208.10 42.302 20 214.35 34.830 20 204.52 39.341 20 226.97 39.664 20 
 Terminal 169.59 39.076 20 181.73 36.618 20 194.91 118.411 20 181.10 27.608 20 
Neutrophils              
10³/µL Day 14 1.644 0.6623 20 1.342 0.5354 20 1.459 0.9791 20 1.513 1.0591 20 
 Day 45 1.464 0.4232 20 1.529 0.4180 20 1.547 0.5776 20 1.543 0.6527 20 

































 0.00 NA 1 NA NA 0 NA NA 0 NA NA 0 
 Terminal
#
 0.00 NA 1 NA NA 0 NA NA 0 NA NA 0 
Lymphocytes              
10³/µL Day 14 7.235 2.4345 20 6.134 1.1550 20 6.124 1.9982 20 6.288 1.3337 20 
 Day 45 8.289 2.5159 20 7.977 2.1527 20 8.581 1.9331 20 8.286 1.7049 20 
 Terminal 11.111 2.5448 20 10.599 1.7700 20 10.775 2.2073 20 10.564 2.1486 20 
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 NA – Not applicable/not available 
 
# 




Table 27-1.  Summary of Hematology Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 

























































 Day 45 0.195 0.0780 20 0.197 0.0538 20 0.177 0.0723 20 0.227 0.0596 20 





























 Day 45 0.120 0.0433 20 0.106 0.0419 20 0.125 0.0447 20 0.120 0.0488 20 





























 Day 45 0.181 0.1023 20 0.175 0.0713 20 0.177 0.0770 20 0.204 0.1009 20 





























 Day 45 0.245 0.7201 20 0.077 0.0262 20 0.073 0.0283 20 0.077 0.0351 20 
 Terminal 0.200 0.0908 20 0.164 0.0615 20 0.169 0.0534 20 0.150 0.0459 20 
              
 
  N - Number of measures used to calculate mean 






Table 27-2.  Summary of Hematology Values – Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Leukocytes              
10³/µL Day 14 6.68 2.210 20 6.98 2.373 20 6.19 1.731 20 7.02 1.670 20 
 Day 45 7.69 2.443 20 8.06 2.326 20 6.73 1.654 20 7.67 1.391 20 































 Day 45 8.398 0.2822 20 8.385 0.3018 20 8.424 0.3069 20 8.489 0.4256 20 































 Day 45 15.62 0.464 20 15.53 0.397 20 14.93 3.113 20 15.68 0.519 20 
 Terminal 15.26 0.511 20 15.26 0.571 20 15.24 0.533 20 15.50 0.638 20 
Hematocrit              
% Day 14 46.16 2.151 20 45.21 2.459 20 46.27 1.740 20 47.07 2.140 20 
 Day 45 46.86 1.580 20 46.56 1.302 20 46.52 1.379 20 46.90 2.075 20 
 Terminal 48.27 1.713 20 48.36 1.797 20 48.25 1.880 20 49.02 2.289 20 
MCV              
fL Day 14 57.01 1.594 20 56.81 1.628 20 56.77 1.320 20 56.53 1.212 20 
 Day 45 55.82 1.478 20 55.56 1.166 20 55.26 1.240 20 55.27 1.058 20 
 Terminal 57.45 1.689 20 56.88 1.441 20 57.00 1.486 20 57.06 1.303 20 
MCH              
pg Day 14 19.68 0.666 20 19.36 0.566 20 19.37 0.453 20 19.30 0.510 20 
 Day 45 18.60 0.529 20 18.54 0.552 20 17.71 3.689 20 18.47 0.446 20 
 Terminal 18.19 0.621 20 17.95 0.588 20 18.01 0.515 20 18.05 0.451 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.




Table 27-2.  Summary of Hematology Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























MCHC              
g/dL Day 14 34.53 1.011 20 34.08 0.616 20 34.12 0.580 20 34.15 0.843 20 
 Day 45 33.35 0.639 20 33.35 0.551 20 32.04 6.632 20 33.45 0.678 20 
 Terminal 31.67 0.612 20 31.57 0.552 20 31.60 0.508 20 31.63 0.486 20 
Platelets              
10³/µL Day 14 928.7 199.81 20 942.7 193.78 20 912.0 184.29 20 910.9 182.66 20 
 Day 45 749.2 168.92 20 778.3 130.94 20 777.4 194.16 20 775.7 145.71 20 
 Terminal 1041.8 137.10 20 1123.7 154.43 20 1074.3 128.69 20 1080.6 92.87 20 
Absolute Reticulocytes              
10³/µL Day 14 170.24 29.162 20 176.71 48.471 20 164.84 36.302 20 160.09 39.784 20 
 Day 45 166.08 32.085 20 176.50 49.006 20 171.18 45.157 20 161.46 30.133 20 
 Terminal 145.55 29.740 20 153.63 47.211 20 138.02 22.191 20 144.08 29.894 20 
Neutrophils              
10³/µL Day 14 1.166 0.5400 20 1.397 1.5650 20 0.976 0.3380 20 1.067 0.5230 20 
 Day 45 1.140 0.5089 20 1.170 0.7138 20 0.985 0.5077 20 0.924 0.4253 20 

































 NA NA 0 NA NA 0 NA NA 0 NA NA 0 
 Terminal
#
 NA NA 0 NA NA 0 NA NA 0 NA NA 0 
Lymphocytes              
10³/µL Day 14 5.163 1.8302 20 5.227 1.8041 20 4.924 1.6725 20 5.569 1.4514 20 
 Day 45 6.085 2.0550 20 6.419 2.1113 20 5.396 1.3534 20 6.337 1.3767 20 
 Terminal 7.980 1.6583 20 9.187 2.4771 20 8.485 1.9923 20 9.317 1.7863 20 
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 NA – Not applicable/not available 
 
# 




Table 27-2.  Summary of Hematology Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Monocytes              
10³/µL Day 14 0.125 0.0599 20 0.155 0.1020 20 0.113 0.0488 20 0.122 0.0508 20 
 Day 45 0.155 0.0487 20 0.166 0.0980 20 0.104
a
 0.0390 20 0.133 0.0533 20 
 Terminal 0.266 0.0942 20 0.313 0.1593 20 0.269 0.0612 20 0.246 0.0834 20 
Eosinophils              
10³/µL Day 14 0.126 0.1242 20 0.081 0.0265 20 0.093 0.0467 20 0.108 0.0574 20 
 Day 45 0.117 0.0622 20 0.110 0.0444 20 0.084 0.0376 20 0.098 0.0402 20 
 Terminal 0.123 0.0566 20 0.130 0.0555 20 0.121 0.0582 20 0.112 0.0437 20 
Basophils              
10³/µL Day 14 0.048 0.0487 20 0.067 0.0775 20 0.042 0.0331 20 0.093 0.1184 20 
 Day 45 0.118 0.0639 20 0.145 0.0838 20 0.099 0.0557 20 0.109 0.0499 20 
 Terminal 0.095 0.0343 20 0.094 0.0390 20 0.083 0.0342 20 0.096 0.0373 20 
Other Cells              
10³/µL Day 14 0.048 0.0253 20 0.045 0.0176 20 0.042 0.0278 20 0.060 0.0589 20 
 Day 45 0.053 0.0245 20 0.052 0.0238 20 0.042 0.0209 20 0.062 0.0274 20 
 Terminal 0.181 0.0903 20 0.157 0.0675 20 0.154 0.0442 20 0.151 0.0745 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 28-1.  Summary of Coagulation Values – Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 






















































































  N - Number of measures used to calculate mean 





Table 28-2.  Summary of Coagulation Values – Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 






















































































  N - Number of measures used to calculate mean 




Table 29-1.  Summary of Clinical Chemistry Values – Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Sodium              
mEq/L Day 14 141.5 1.32 20 141.9 1.39 20 142.0 1.12 20 141.4 1.60 20 
 Day 45 142.2 1.44 20 141.5 1.05 20 142.1 1.32 20 141.7 1.87 20 
 Terminal 145.3 1.69 20 145.7 2.32 20 145.4 1.46 20 144.9 1.45 20 
Potassium              
mEq/L Day 14 5.58 0.464 20 5.92 0.647 20 5.87 0.820 20 5.98 0.425 20 
 Day 45 5.47 0.323 20 5.88
a
 0.401 20 5.66 0.358 20 5.84a 0.616 20 
 Terminal 6.30 0.849 20 6.20 1.053 20 6.30 0.972 20 6.20 0.827 20 
Chloride              
mEq/L Day 14 100.0 1.43 20 100.3 1.16 20 100.6 1.60 20 100.0 1.59 20 
 Day 45 100.8 1.74 20 100.5 1.28 20 100.5 1.50 20 99.8 2.17 20 
 Terminal 99.1 1.59 20 98.9 1.79 20 99.0 1.26 20 98.7 1.59 20 
Calcium              
mg/dL Day 14 10.22 0.246 20 10.28 0.245 20 10.16 0.278 20 10.11 0.286 20 
 Day 45 10.26 0.258 20 10.19 0.399 20 10.18 0.245 20 10.38 0.330 20 
 Terminal 11.43 0.423 20 11.43 0.337 20 11.44 0.416 20 11.44 0.356 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Phosphorus              
mg/dL Day 14 8.74 0.583 20 8.94 0.701 20 8.89 0.672 20 8.88 0.471 20 
 Day 45 7.57 0.407 20 7.47 0.590 20 7.39 0.499 20 7.81 0.381 20 
 Terminal 8.29 0.880 20 8.19 0.835 20 8.17 0.773 20 8.34 0.724 20 
Alkaline Phosphatase              
U/L Day 14 239.5 39.62 20 222.3 45.23 20 249.7 39.81 20 231.1 48.58 20 
 Day 45 178.2 35.29 20 161.7 48.48 20 174.5 36.66 20 162.9 41.98 20 
 Terminal 99.1 19.52 20 91.5 25.71 20 94.0 27.73 20 86.8 17.03 20 
Total Bilirubin              
mg/dL Day 14 0.11 0.031 20 0.11 0.031 20 0.10 0.000 20 0.11 0.022 20 
 Day 45 0.16 0.050 20 0.16 0.051 20 0.15 0.051 20 0.13 0.044 20 
 Terminal 0.13 0.044 20 0.11 0.022 20 0.10a 0.000 20 0.11 0.031 20 
AST              
U/L Day 14 133.3 23.12 20 129.3 23.35 20 123.6 21.06 20 129.7 19.06 20 
 Day 45 108.3 18.17 20 112.7 23.10 20 110.2 19.00 20 111.2 14.31 20 
 Terminal 71.4 8.76 20 70.1 15.84 20 69.0 13.25 20 64.2 10.13 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























ALT              
U/L Day 14 34.5 6.91 20 31.9 4.97 20 31.4 4.32 20 33.3 4.46 20 
 Day 45 36.7 4.56 20 37.7 5.98 20 36.9 3.41 20 36.8 5.53 20 





























 Day 45 11.7 1.66 20 12.2 1.79 20 12.1 1.62 20 12.8 1.96 20 
 Terminal 14.1 2.63 20 14.2 1.73 20 13.9 1.57 20 13.8 1.89 20 
Creatinine              
mg/dL Day 14 0.35 0.051 20 0.34 0.075 20 0.33 0.044 20 0.32 0.037 20 
 Day 45 0.34 0.050 20 0.34 0.050 20 0.35 0.051 20 0.34 0.050 20 
 Terminal 0.42 0.037 20 0.41 0.022 20 0.42 0.041 20 0.40 0.046 20 
Total Protein              
g/dL Day 14 6.17 0.320 20 6.09 0.216 20 6.17 0.274 20 6.02 0.230 20 
 Day 45 6.51 0.258 20 6.45 0.298 20 6.62 0.250 20 6.62 0.333 20 
 Terminal 6.47 0.281 20 6.53 0.283 20 6.57 0.359 20 6.68 0.334 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Albumin              
g/dL Day 14 3.41 0.194 20 3.36 0.119 20 3.40 0.130 20 3.30 0.156 20 
 Day 45 3.41 0.162 20 3.34 0.142 20 3.43 0.097 20 3.44 0.139 20 
 Terminal 3.28 0.224 20 3.30 0.169 20 3.31 0.161 20 3.29 0.162 20 
Globulin              
g/dL Day 14 2.76 0.198 20 2.73 0.162 20 2.77 0.193 20 2.72 0.176 20 
 Day 45 3.10 0.182 20 3.11 0.220 20 3.20 0.233 20 3.18 0.231 20 
 Terminal 3.19 0.253 20 3.23 0.200 20 3.26 0.241 20 3.39a 0.223 20 
Albumin/Globulin Ratio              
 Day 14 1.25 0.094 20 1.25 0.089 20 1.24 0.088 20 1.22 0.106 20 
 Day 45 1.11 0.076 20 1.07 0.080 20 1.08 0.077 20 1.09 0.067 20 
 Terminal 1.05 0.115 20 1.03 0.085 20 1.02 0.075 20 0.98 0.070 20 
Triglyceride              
mg/dL Day 14 54.5 15.03 20 55.9 15.70 20 47.9 12.73 20 56.0 15.73 20 
 Day 45 82.8 32.07 20 70.7 24.47 20 71.3 24.49 20 73.5 19.61 20 
 Terminal 70.2 34.27 20 74.0 34.36 20 64.0 26.15 20 65.6 25.92 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.





Table 29-1.  Summary of Clinical Chemistry Values – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Cholesterol              
mg/dL Day 14 56.4 9.69 20 64.2 14.99 20 57.0 11.42 20 62.8 9.59 20 
 Day 45 63.7 11.19 20 73.1 20.78 20 69.3 14.75 20 81.8
b
 13.89 20 
 Terminal 58.9 15.55 20 70.8 24.95 20 66.4 15.99 20 79.5b 14.81 20 
Glucose              
mg/dL Day 14 81.5 6.79 20 83.5 6.58 20 79.7 8.70 20 81.7 6.64 20 
 Day 45 93.2 9.86 20 95.4 9.63 20 90.6 10.14 20 91.7 9.53 20 
 Terminal 196.5 40.48 20 190.9 44.48 20 203.7 56.20 20 180.6 34.10 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-2.  Summary of Clinical Chemistry Values – Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Sodium              
mEq/L Day 14 139.9 1.68 20 140.0 1.62 20 139.3 1.12 20 139.6 1.98 20 
 Day 45 140.8 1.40 20 140.7 1.42 20 141.1 1.80 20 140.5 1.40 20 





























 Day 45 5.32 0.492 20 5.47 0.594 20 5.20 0.588 20 5.43 0.566 20 
 Terminal 7.06 0.536 20 6.95 0.561 20 6.88 1.023 20 7.02 0.653 20 
Chloride              
mEq/L Day 14 100.9 1.74 20 101.0 1.12 20 100.2 1.32 20 100.4 1.43 20 
 Day 45 101.7 2.43 20 101.1 1.39 20 101.5 1.90 20 101.2 1.61 20 
 Terminal 99.8 1.33 20 100.2 1.61 20 99.4 1.63 20 99.6 1.60 20 
Calcium              
mg/dL Day 14 10.22 0.358 20 10.24 0.372 20 10.25 0.310 20 10.19 0.270 20 
 Day 45 10.44 0.428 20 10.31 0.501 20 10.27 0.333 20 10.35 0.319 20 
 Terminal 11.90 0.502 20 11.84 0.365 20 12.06 0.538 20 11.90 0.405 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 

























































 Day 45 5.96 0.763 20 6.37 0.615 20 5.79 0.735 20 5.99 0.769 20 
 Terminal 7.80 0.732 20 8.03 0.759 20 8.07 0.668 20 8.21 0.841 20 
Alkaline Phosphatase              
U/L Day 14 127.5 31.16 20 138.1 36.02 20 137.7 34.50 20 126.6 27.00 20 
 Day 45 99.1 25.96 20 100.5 35.95 20 103.7 34.95 20 91.8 28.31 20 
 Terminal 45.2 9.94 20 53.4 21.40 20 55.8 21.78 20 50.8 12.25 20 
Total Bilirubin              
mg/dL Day 14 0.13 0.047 20 0.12 0.037 20 0.13 0.047 20 0.13 0.044 20 
 Day 45 0.15 0.051 20 0.17 0.049 20 0.15 0.051 20 0.15 0.051 20 
 Terminal 0.13 0.044 20 0.12 0.037 20 0.14 0.049 20 0.11 0.031 20 
AST              
U/L Day 14 119.3 23.14 20 112.9 27.53 20 107.7 19.85 20 122.6 20.52 20 
 Day 45 100.2 19.32 20 100.8 20.98 20 96.2 17.39 20 102.2 32.02 20 
 Terminal 101.0 100.72 20 75.3 34.06 20 77.4 62.06 20 62.1 9.88 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























ALT              
U/L Day 14 32.0 3.61 20 30.5 5.32 20 29.2 4.94 20 30.3 4.12 20 
 Day 45 40.0 6.93 20 36.2 7.84 20 35.1 5.76 20 34.7 18.43 20 
 Terminal 54.2 78.04 20 35.8 22.31 20 37.3 25.83 20 27.7 5.14 20 
Urea Nitrogen              
mg/dL Day 14 15.3 1.89 20 14.4 2.23 20 13.9 1.21 20 14.2 1.96 20 
 Day 45 13.4 1.47 20 12.9 2.68 20 13.7 2.18 20 13.2 2.35 20 
 Terminal 14.1 1.77 20 15.3 4.01 20 15.5 3.19 20 14.9 2.47 20 
Creatinine              
mg/dL Day 14 0.39 0.059 20 0.35 0.051 20 0.36 0.051 20 0.38 0.095 20 
 Day 45 0.40 0.056 20 0.37 0.047 20 0.40 0.032 20 0.40 0.051 20 





























 Day 45 7.11 0.411 20 6.79
a
 0.294 20 7.12 0.354 20 7.14 0.362 20 
 Terminal 7.17 0.493 20 6.94 0.390 20 7.14 0.550 20 7.01 0.400 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 





























Albumin              
g/dL Day 14 3.68 0.207 20 3.55 0.147 20 3.67 0.149 20 3.67 0.187 20 
 Day 45 3.84 0.260 20 3.66
a
 0.193 20 3.86 0.209 20 3.85 0.214 20 
 Terminal 3.82 0.312 20 3.66 0.230 20 3.81 0.352 20 3.70 0.229 20 
Globulin              
g/dL Day 14 2.84 0.176 20 2.71 0.192 20 2.83 0.183 20 2.87 0.218 20 
 Day 45 3.27 0.232 20 3.13 0.262 20 3.26 0.224 20 3.29 0.174 20 
 Terminal 3.35 0.212 20 3.28 0.221 20 3.33 0.275 20 3.31 0.220 20 
Albumin/Globulin Ratio              
 Day 14 1.30 0.100 20 1.32 0.075 20 1.30 0.086 20 1.29 0.088 20 
 Day 45 1.19 0.102 20 1.19 0.125 20 1.20 0.108 20 1.17 0.047 20 
 Terminal 1.16 0.076 20 1.13 0.085 20 1.15 0.105 20 1.12 0.077 20 
Triglyceride              
mg/dL Day 14 43.1 13.76 20 38.2 12.06 20 41.9 14.63 20 35.9 9.80 20 
 Day 45 50.6 19.69 20 37.4
a
 8.31 20 37.5a 10.03 20 37.4a 8.64 20 
 Terminal 41.3 12.46 20 40.8 12.77 20 46.2 14.25 20 41.6 10.52 20 
              
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
 
a.






Table 29-2.  Summary of Clinical Chemistry Values – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 

























































 Day 45 79.6 15.36 20 74.8 11.24 20 80.0 14.99 20 75.2 12.33 20 





























 Day 45 95.0 13.81 20 92.7 11.97 20 94.6 16.11 20 91.1 13.75 20 
 Terminal 181.1 34.18 20 169.3 18.78 20 181.6 23.55 20 182.2 32.45 20 
              
 
  N - Number of measures used to calculate mean 






Table 30-1.  Summary of Urinalysis Values – Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 

















































































































Table 30-2.  Summary of Urinalysis Values – Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 













































































































              
 
  N - Number of measures used to calculate mean 




Table 31-1.  Summary of Macroscopic Observations – Male 
MPI Research Study No. 1646-014 




0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Tissue 
   Observation 
Severity 
    
Number of Animals Examined  20 20 20 20 
all tissues 











     
   small - mild 0 0 1 0 
lung with bronchi 













     
    cyst - mild 1 0 0 0 
testes 

















Table 31-2.  Summary of Macroscopic Observations – Female 
MPI Research Study No. 1646-014 




0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
Tissue 
   Observation 
 Severity 
    
Number of Animals Examined  20 20 20 20 
all tissues 











     
   enlarged - moderate 0 1 0 0 
kidneys 
   absent 
 









   dilatation, pelvic - mild 1 1 0 0 
   focus/foci, red - mild 0 1 0 0 
   irregular surface - moderate 0 1 0 0 
 
thyroid gland 
     
   small - moderate 0 0 1 0 
ureters 
   absent 
 









   dilatation - mild 1 0 0 0 
   distended with urine - mild 0 1 0 0 
urinary bladder 











      
uterus with cervix 
   absent, portion 
 









   enlarged  - moderate 0 1 0 0 




Table 32-1.  Summary of Organ Weight Values – Male 
MPI Research Study No. 1646-014 


















































































































































Adrenal gl/BWt             




























            
 
  N - Number of measures used to calculate mean 






Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 






























































































Epididymides/BrWt             
ratio 0.7001 0.0816 20 0.6409 0.0566 20 0.6716 0.0747 19 0.7050 0.0989 20 
Heart             
g 1.773 0.238 20 1.772 0.248 20 1.791 0.229 20 1.794 0.206 20 
Heart/BWt             
% 0.3394 0.0409 20 0.3343 0.0346 20 0.3455 0.0456 20 0.3488 0.0332 20 
Heart/BrWt             
ratio 0.8161 0.1183 20 0.8262 0.1239 20 0.8246 0.0961 20 0.8310 0.0944 20 
             
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.







Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 











































            
g 3.874 0.397 20 3.935 0.434 20 3.912 0.393 20 4.013 0.524 20 
Kidneys/BWt             
% 0.7407 0.0478 20 0.7432 0.0560 20 0.7536 0.0670 20 0.7781 0.0651 20 
Kidneys/BrWt             
ratio 1.7807 0.1668 20 1.8332 0.2087 20 1.8000 0.1239 20 1.8583 0.2446 20 
Liver             






















































            
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.
 Significantly different from control; (p< 0.05) 
b.






Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 







































































































































































































            
 
  N - Number of measures used to calculate mean 





Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 











































            
g 1.664 0.399 20 1.710 0.346 20 1.753 0.319 20 1.817 0.445 20 
Prostate gl/BWt             
% 0.3193 0.0765 20 0.3252 0.0695 20 0.3403 0.0748 20 0.3492 0.0686 20 
Prostate gl/BrWt             





















































Sem. ves./BrWt             
ratio 0.9477 0.1391 20 0.8393 0.1312 20 0.8777 0.1966 20 0.8498 0.1591 20 
             
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.






Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 







































































































































































































            
 
  N - Number of measures used to calculate mean 






Table 32-1.  Summary of Organ Weight Values – Male (continued) 
MPI Research Study No. 1646-014 







































































































































































































            
 
  N - Number of measures used to calculate mean 






Table 32-2.  Summary of Organ Weight Values – Female 
MPI Research Study No. 1646-014 




































































Brain             
g 1.979 0.108 20 1.995 0.099 20 1.988 0.093 20 1.944 0.099 20 
Brain/BWt             
% 0.7343 0.0643 20 0.7428 0.0568 20 0.7408 0.0502 20 0.7723 0.0584 20 
Adrenal gl             
g 0.069 0.015 20 0.070 0.012 20 0.076 0.016 20 0.062 0.013 20 
Adrenal gl/BWt             
% 0.0256 0.0047 20 0.0262 0.0048 20 0.0281 0.0061 20 0.0245 0.0052 20 
Adrenal gl/BrWt             
ratio 0.0352 0.0083 20 0.0352 0.0058 20 0.0380 0.0080 20 0.0319 0.0069 20 
             
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.






Table 32-2.  Summary of Organ Weight Values – Female (continued) 
MPI Research Study No. 1646-014 











































            
g 1.045 0.128 20 1.044 0.071 20 1.032 0.118 20 0.967 0.091 20 
Heart/BWt             
% 0.3854 0.0333 20 0.3885 0.0311 20 0.3841 0.0437 20 0.3833 0.0300 20 
Heart/BrWt             
ratio 0.5287 0.0652 20 0.5243 0.0398 20 0.5195 0.0576 20 0.4979 0.0415 20 
Kidneys             



























Kidneys/BrWt             
ratio 1.0160 0.1055 20 1.0476 0.0905 19 1.0708 0.1138 20 1.0456 0.1270 19 
             
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.
 Significantly different from control; (p< 0.05) 
b.






Table 32-2.  Summary of Organ Weight Values – Female (continued) 
MPI Research Study No. 1646-014 











































            



























Liver/BrWt             
ratio 3.9759 0.5667 20 3.9225 0.4749 20 4.1059 0.4997 20 4.0581 0.4349 20 
Lung w/ bronchi             
g 1.411 0.237 20 1.383 0.216 20 1.434 0.271 20 1.448 0.250 20 
Lung w/ bronchi/BWt             
% 0.5200 0.0737 20 0.5124 0.0656 20 0.5329 0.1012 20 0.5718 0.0762 20 
Lung w/ bronchi/BrWt             
ratio 0.7156 0.1381 20 0.6939 0.1062 20 0.7215 0.1370 20 0.7448 0.1193 20 
             
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.






Table 32-2.  Summary of Organ Weight Values – Female (continued) 
MPI Research Study No. 1646-014 






































































































































































































            
 
  N - Number of measures used to calculate mean 






Table 32-2.  Summary of Organ Weight Values – Female (continued) 
MPI Research Study No. 1646-014 











































            



























Spleen/BrWt             



























Thymus/BWt             




























            
 
  N - Number of measures used to calculate mean 
  SD - Standard Deviation 
a.
 Significantly different from control; (p< 0.05) 
b.






Table 32-2.  Summary of Organ Weight Values – Female (continued) 
MPI Research Study No. 1646-014 







































































































































































































            
 
  N - Number of measures used to calculate mean 






Table 33-1.  Summary of Microscopic Observations – Male 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
adrenal glands  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
aorta  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone marrow, femur  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone marrow, sternum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone, femur  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone, sternum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
brain  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
       





Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
epididymides  (20) (0) (1) (20) 
   anomaly, developmental  - no grade 0 0 1 0 
   within normal limits  20 0 0 20 
esophagus  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
eyes  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
eyes, optic nerves  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
galt  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
heart  (20) (0) (0) (20) 
   cardiomyopathy  7 0 0 5 
 - minimal 6 0 0 3 
 - mild 1 0 0 2 
   within normal limits  13 0 0 15 
joint, tibiofemoral  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 





Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
kidneys  (20) (0) (0) (20) 
   cyst - mild 1 0 0 0 
   inflammation, perivascular - mild 1 0 0 0 
   nephropathy, chronic progressive - minimal 7 0 0 7 
   within normal limits  13 0 0 13 
lacrimal glands, exorbital  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, cecum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, colon  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, rectum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
larynx  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
liver  (20) (20) (20) (20) 
   hematopoiesis, extramedullary - mild 1 0 0 0 
      
 






Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
liver  (20) (20) (20) (20) 
   hypertrophy, hepatocyte, centrilobular - minimal 0 0 0 3 
   infiltration, mononuclear cell - minimal 20 19 20 16 
   necrosis, focal - minimal 0 1 0 0 
   within normal limits  0 1 0 4 
lung  (20) (0) (0) (20) 
   hemorrhage  3 0 0 1 
 - minimal 2 0 0 0 
 - mild 1 0 0 1 
   histiocytosis, alveolar - minimal 5 0 0 5 
   inflammation, subacute - minimal 1 0 0 2 
   within normal limits  12 0 0 12 
lymph node, mandibular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
lymph node, mesenteric  (20) (0) (0) (20) 
   inflammation, perivascular - minimal 1 0 0 0 
   within normal limits  19 0 0 20 
nerve, sciatic  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
pancreas  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
parathyroid glands  (16) (0) (0) (16) 
   within normal limits  16 0 0 16 
pituitary gland  (20) (0) (0) (20) 
   cyst  3 0 0 0 
 - minimal 1 0 0 0 
 - mild 2 0 0 0 
   within normal limits  17 0 0 20 
prostate gland  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
salivary gland, mandibular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
salivary gland, parotid  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
salivary gland, sublingual  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
seminal vesicles  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
skeletal muscle, biceps femoris  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
skin  (20) (0) (0) (20) 
   exudate, epidermal surface - minimal 0 0 0 1 
   within normal limits  20 0 0 19 
small intestine, duodenum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
small intestine, ileum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
small intestine, jejunum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spinal cord, cervical  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spinal cord, lumbar  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
spinal cord, thoracic  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spleen  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
stomach, glandular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
stomach, nonglandular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
testes  (20) (0) (1) (20) 
   anomaly, developmental - no grade 0 0 1 0 
   within normal limits  20 0 0 20 
thymus  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
thyroid gland  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-1.  Summary of Microscopic Observations – Male (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
tongue  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
trachea  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
ureters  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
urinary bladder  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
adrenal glands  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
aorta  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone marrow, femur  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone marrow, sternum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone, femur  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
bone, sternum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
brain  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
clitoral glands  (0) (1) (0) (0) 
   dilatation - mild 0 1 0 0 
   hyperplasia - mild 0 1 0 0 
esophagus  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
eyes  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
eyes, optic nerves  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
galt  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
heart  (20) (0) (0) (20) 
   cardiomyopathy - minimal 2 0 0 2 
   within normal limits  18 0 0 18 
joint, tibiofemoral  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
kidneys  (20) (2) (0) (20) 
   carcinoma, renal tubule, amphophilic-vacuolar (av) type,        
   malignant, primary 
 0 1 0 0 
   hydronephrosis, bilateral - minimal 0 0 0 1 
   hydronephrosis, unilateral - minimal 1 0 0 0 
   mineralization - minimal 3 0 0 0 
   nephropathy, chronic progressive - minimal 1 0 0 0 
   pyelitis - minimal 1 0 0 0 
   within normal limits  15 1 0 19 
lacrimal glands, exorbital  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, cecum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, colon  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
large intestine, rectum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
larynx  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
liver  (20) (20) (20) (20) 
   infiltration, mononuclear cell - minimal 18 17 18 17 
   within normal limits  2 3 2 3 
lung  (20) (0) (0) (20) 
   hemorrhage - minimal 1 0 0 0 
   histiocytosis, alveolar - minimal 5 0 0 2 
   inflammation, subacute - minimal 1 0 0 1 
   within normal limits  14 0 0 17 
lymph node, mandibular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
lymph node, mesenteric  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
mammary gland  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
nerve, sciatic  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
ovaries  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
oviducts  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
pancreas  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
parathyroid glands  (17) (0) (0) (15) 
   within normal limits  17 0 0 15 
pituitary gland  (20) (0) (0) (20) 
   cyst  1 0 0 1 
 - minimal 1 0 0 0 
 - mild 0 0 0 1 
   within normal limits  19 0 0 19 
salivary gland, mandibular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
salivary gland, parotid  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
salivary gland, sublingual  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
skeletal muscle, biceps femoris  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
skin  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
small intestine, duodenum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
small intestine, ileum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
small intestine, jejunum  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spinal cord, cervical  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spinal cord, lumbar  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 






Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
spinal cord, thoracic  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
spleen  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
stomach, glandular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
stomach, nonglandular  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
thymus  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
thyroid gland  (20) (0) (1) (20) 
   hyperplasia, c-cell, focal - mild 0 0 0 1 
   within normal limits  20 0 1 19 
tongue  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
trachea  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 







Table 33-2.  Summary of Microscopic Observations – Female (continued) 
MPI Research Study No. 1646-014 
S3643: A 13 Week Dietary Administration Toxicity Study in Rats 
 
Tissue  0 mg/kg/day 10 mg/kg/day 30 mg/kg/day 100 mg/kg/day 
   Observation Severity  
Number of Animals Examined  20 20 20 20 
ureters  (20) (1) (0) (20) 
   dilatation  1 1 0 0 
 - minimal 1 0 0 0 
 - moderate 0 1 0 0 
   hyperplasia, transitional cell - moderate 0 1 0 0 
   within normal limits  19 0 0 20 
urinary bladder  (20) (1) (0) (20) 
   hyperplasia, papillary/nodular transitional cell - moderate 0 1 0 0 
   within normal limits  20 0 0 20 
uterus with cervix  (20) (1) (0) (20) 
   leiomyoma, benign, primary  0 1 0 0 
   within normal limits  20 0 0 20 
vagina  (20) (0) (0) (20) 
   within normal limits  20 0 0 20 
      
 
( ) – Number observed 
 
 
 
